[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 45 of about 45
1. Vilaplana Palomer J: [Incessant atrial tachycardia and a cerebral tumor]. Rev Esp Cardiol; 2003 May;56(5):519-22
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Incessant atrial tachycardia and a cerebral tumor].
  • [Transliterated title] Taquicardia auricular incesante y tumoración cerebral.
  • We report the case of an asymptomatic 78-year-old woman in whom incessant atrial tachycardia refractory to many pharmacological treatments appeared.
  • Months after the appearance of atrial tachycardia, clinical neurological symptoms of a cerebral cystic tumor appeared.
  • Treatment of the tumor resolved the rhythm disorder.
  • [MeSH-major] Brain Neoplasms / complications. Cysts / complications. Tachycardia, Ectopic Atrial / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12737792.001).
  • [ISSN] 0300-8932
  • [Journal-full-title] Revista española de cardiología
  • [ISO-abbreviation] Rev Esp Cardiol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


2. Choi JW, Lee MM, Kim IA, Kim JH, Choe G, Kim CY: The outcomes of concomitant chemoradiotherapy followed by adjuvant chemotherapy with temozolomide for newly diagnosed high grade gliomas : the preliminary results of single center prospective study. J Korean Neurosurg Soc; 2008 Oct;44(4):222-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The outcomes of concomitant chemoradiotherapy followed by adjuvant chemotherapy with temozolomide for newly diagnosed high grade gliomas : the preliminary results of single center prospective study.
  • OBJECTIVE: Malignant gliomas are the most common primary cerebral neoplasms in adults.
  • Despite multimodality treatments, the prognosis for patients with malignant glioma remains poor.
  • We report for the first time preliminary results of the treatment with CCRT of newly diagnosed malignant gliomas in Korean people.
  • At the time of this analysis, 13 patients died and three patients had been lost to follow-up.
  • There was no mortality caused by drug toxicity.
  • CONCLUSION: Our results are consistent with many other reports, confirming that CCRT with TMZ achieves good clinical outcomes in the treatment of HGG.
  • Therefore, we suggest that CCRT with TMZ as adjuvant chemotherapy be considered as a standard therapy for patients with HGG.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2008 May 1;26(13):2192-7 [18445844.001]
  • [Cites] Br J Cancer. 2000 Apr;82(8):1371-80 [10780513.001]
  • [Cites] Neurol Clin. 2007 Nov;25(4):1111-39, x [17964028.001]
  • [Cites] J Clin Oncol. 2007 Sep 10;25(26):4127-36 [17827463.001]
  • [Cites] Crit Rev Oncol Hematol. 2006 Nov;60(2):99-111 [17027279.001]
  • [Cites] Tumori. 2006 Jul-Aug;92(4):299-305 [17036520.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • [Cites] Cancer Radiother. 2005 Sep;9(5):322-31 [16095943.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Strahlenther Onkol. 2005 Mar;181(3):157-63 [15756519.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3851-7 [9850030.001]
  • [Cites] J Neurosurg. 1989 Dec;71(6):826-36 [2585073.001]
  • [Cites] N Engl J Med. 1980 Dec 4;303(23):1323-9 [7001230.001]
  • [Cites] J Neurosurg. 1978 Sep;49(3):333-43 [355604.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1375-82 [11870182.001]
  • [Cites] Ann Oncol. 2001 Feb;12(2):259-66 [11300335.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):588-93 [10944597.001]
  • [Cites] Can J Neurol Sci. 2007 Nov;34(4):402-10 [18062446.001]
  • (PMID = 19096681.001).
  • [ISSN] 2005-3711
  • [Journal-full-title] Journal of Korean Neurosurgical Society
  • [ISO-abbreviation] J Korean Neurosurg Soc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2588321
  • [Keywords] NOTNLM ; Concomitant chemoradiotherapy / Glioblastoma / High-grade glioma / Temozolomide
  •  go-up   go-down


3. Cherif J, M'hamdi S, Osman M, Mehiri N, Zouaoui A, Zouheir S, Louzir B, Béji M: Transitory, spontaneously recovering, peripheral facial nerve palsy after vionorelbine administration. Tunis Med; 2010 Jul;88(7):513-6
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE REPORT: We report the case of a 50 year old man, having stage IV lung carcinoma with a unique cerebral metastasis in the right hemisphere.
  • Focal cerebral radiotherapy was first administrated followed by intravenous chemotherapy associating vinorelbine to cisplatin.
  • He has developed multiple subsequent and transitory episodes of monolateral peripheral facial nerve palsy in the left side during vinorelbine administration.
  • The palsy has completely and spontaneously resolved at a short interval, around twenty minutes, after the end of the drug infusion.
  • Obvious cerebral tumor progression was excluded by means of CT scan; the drug was thereby administrated as scheduled until the end of the treatment.
  • CONCLUSION: We describe an unusual side effect, until now reported in only two cases, having brain-stem gliomas, among English and French literature, dealing with vinorelbine as adjuvant treatment.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Brain Neoplasms / complications. Brain Neoplasms / drug therapy. Carcinoma, Non-Small-Cell Lung / complications. Carcinoma, Non-Small-Cell Lung / drug therapy. Facial Paralysis / etiology. Vinblastine / analogs & derivatives
  • [MeSH-minor] Humans. Lung Neoplasms / pathology. Male. Middle Aged. Remission, Spontaneous

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20582890.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Tunisia
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 5V9KLZ54CY / Vinblastine; Q6C979R91Y / vinorelbine
  •  go-up   go-down


Advertisement
4. Delemarre EM, Felius B, Delemarre-van de Waal HA: Inducing puberty. Eur J Endocrinol; 2008 Dec;159 Suppl 1:S9-15
Hazardous Substances Data Bank. TESTOSTERONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hypogonadotropic hypogonadism may present in a congenital form caused by developmental disorders, some of which are related to a genetic disorder, or secondary to hypothalamic-pituitary dysfunction due to, among others, a cerebral tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18796540.001).
  • [ISSN] 1479-683X
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Androgens; 0 / Estrogens; 0 / Gonadotropins; 33515-09-2 / Gonadotropin-Releasing Hormone; 3XMK78S47O / Testosterone
  • [Number-of-references] 48
  •  go-up   go-down


5. Shelton LM, Huysentruyt LC, Seyfried TN: Glutamine targeting inhibits systemic metastasis in the VM-M3 murine tumor model. Int J Cancer; 2010 Nov 15;127(10):2478-85
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glutamine targeting inhibits systemic metastasis in the VM-M3 murine tumor model.
  • Current therapeutic options consist of chemotherapy, radiation or targeted therapies.
  • However, these therapies are often toxic, effective over a small range of cancer types or result in drug resistance.
  • We found that primary tumor growth was ∼20-fold less in DON-treated mice than in untreated control mice.
  • We also found that DON treatment inhibited metastasis to liver, lung and kidney as detected by bioluminescence imaging and histology.
  • Our findings provide proof of concept that metabolic therapies targeting glutamine metabolism can manage systemic metastatic cancer.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GLUCOSE .
  • Hazardous Substances Data Bank. Glutamine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Adv Pharmacol Chemother. 1970;8:57-120 [4400179.001]
  • [Cites] Cytopathology. 2006 Oct;17(5):304-5 [16961662.001]
  • [Cites] Scand J Haematol. 1973;11(3):253-6 [4128872.001]
  • [Cites] J Biol Chem. 1979 Apr 25;254(8):2669-76 [429309.001]
  • [Cites] J Biol Chem. 1979 Apr 25;254(8):2835-8 [429321.001]
  • [Cites] Cancer Res. 1979 Aug;39(8):3220-4 [572261.001]
  • [Cites] Arch Pathol Lab Med. 1980 Dec;104(12):651-3 [6893661.001]
  • [Cites] Physiol Genomics. 2006 Nov 27;27(3):187-200 [16882887.001]
  • [Cites] N Engl J Med. 2006 Dec 28;355(26):2783-5 [17192546.001]
  • [Cites] Prostate. 2007 Aug 1;67(11):1211-8 [17525933.001]
  • [Cites] Transplantation. 2007 Jul 27;84(2):272-4 [17667822.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Sep 1;69(1):214-20 [17707275.001]
  • [Cites] Cancer Lett. 2007 Dec 18;258(2):155-64 [17977647.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19345-50 [18032601.001]
  • [Cites] Annu Rev Pathol. 2008;3:221-47 [18233952.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):73-84 [18398829.001]
  • [Cites] Cell Cycle. 2008 Jul 15;7(14):2083-9 [18635953.001]
  • [Cites] J Cutan Pathol. 2009 Jan;36(1):64-6 [18715256.001]
  • [Cites] Mol Cancer Ther. 2009 Jan;8(1):10-6 [19139108.001]
  • [Cites] Oral Oncol. 2009 Feb;45(2):148-55 [18635390.001]
  • [Cites] Curr Treat Options Oncol. 2008 Dec;9(4-6):326-42 [19225891.001]
  • [Cites] Science. 2009 Jul 31;325(5940):612-6 [19644120.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Sep 1;106(35):14878-83 [19706488.001]
  • [Cites] Cancer Res. 2009 Oct 15;69(20):7986-93 [19826036.001]
  • [Cites] Int J Cancer. 2010 Jan 1;126(1):65-72 [19536778.001]
  • [Cites] Clin Cancer Res. 2008 Dec 1;14(23):7751-62 [19047102.001]
  • [Cites] Free Radic Biol Med. 2000 Nov 1;29(9):913-23 [11063916.001]
  • [Cites] Br J Cancer. 2001 Apr 20;84(8):1107-14 [11308262.001]
  • [Cites] J Nutr. 2001 Sep;131(9 Suppl):2475S-85S; discussion 2486S-7S [11533296.001]
  • [Cites] J Nutr. 2001 Sep;131(9 Suppl):2539S-42S; discussion 2550S-1S [11533309.001]
  • [Cites] Br J Cancer. 2002 May 20;86(10):1615-21 [12085212.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):563-72 [12154349.001]
  • [Cites] Int J Cancer. 2002 Oct 10;101(5):496-9 [12216080.001]
  • [Cites] Cell Biochem Funct. 2003 Mar;21(1):1-9 [12579515.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):1150-9 [14871995.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5622-9 [15328205.001]
  • [Cites] Cancer. 1985 Oct 1;56(7 Suppl):1778-82 [4027909.001]
  • [Cites] Am J Physiol. 1986 Jul;251(1 Pt 1):E117-26 [2873746.001]
  • [Cites] J Biol Chem. 1990 Jul 5;265(19):11377-81 [2358467.001]
  • [Cites] Tokushima J Exp Med. 1992 Jun;39(1-2):69-76 [1412455.001]
  • [Cites] Cancer Res. 1994 Apr 1;54(7):1690-4 [8137283.001]
  • [Cites] Int J Biochem. 1993 Dec;25(12):1749-55 [8138012.001]
  • [Cites] Cell Biochem Funct. 1996 Mar;14(1):1-10 [8907248.001]
  • [Cites] J Neurooncol. 1998 Apr;37(2):97-108 [9524087.001]
  • [Cites] Am J Physiol. 1998 May;274(5 Pt 1):E801-7 [9612237.001]
  • [Cites] Cancer Lett. 1998 Nov 13;133(1):95-9 [9929166.001]
  • [Cites] Cancer. 1957 Nov-Dec;10(6):1138-50 [13489662.001]
  • [Cites] Cancer Res. 1959 May;19(4):388-92 [13652122.001]
  • [Cites] Neuro Oncol. 2005 Apr;7(2):177-82 [15831235.001]
  • [Cites] J Clin Neurosci. 2005 May;12(4):379-82 [15925766.001]
  • [Cites] Br J Neurosurg. 2005 Aug;19(4):348-51 [16455543.001]
  • [Cites] Br J Cancer. 2006 Mar 13;94(5):614-9 [16465192.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3629-38 [16585188.001]
  • [Cites] Nat Rev Cancer. 2006 Jun;6(6):449-58 [16723991.001]
  • [Cites] Proc R Soc Lond B Biol Sci. 1972 Jul 25;182(1066):25-35 [4403084.001]
  • (PMID = 20473919.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS055195-05A2; United States / NCI NIH HHS / CA / R01 CA102135-01A1; United States / NINDS NIH HHS / NS / NS-055195; United States / NCI NIH HHS / CA / CA-102135; United States / NINDS NIH HHS / NS / R01 NS055195; United States / NCI NIH HHS / CA / R01 CA102135; United States / NINDS NIH HHS / NS / R56 NS055195; United States / NINDS NIH HHS / NS / R01 NS055195-05A2; United States / NCI NIH HHS / CA / CA102135-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Blood Glucose; 03J0H273KZ / Diazooxonorleucine; 0RH81L854J / Glutamine; IY9XDZ35W2 / Glucose
  • [Other-IDs] NLM/ NIHMS216117; NLM/ PMC2946425
  •  go-up   go-down


6. López Almaraz R, Villafruela Alvarez C, Rodríguez Luis J, Doménech Martínez E: [Neonatal neoplasms: a single-centre experience]. An Pediatr (Barc); 2006 Dec;65(6):529-35

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neonatal neoplasms: a single-centre experience].
  • OBJECTIVES: To describe the neoplasms diagnosed and treated in newborns (</= 28 days of life) in the Hospital Universitario de Canarias and their association with congenital abnormalities and to evaluate prenatal diagnosis of these tumors.
  • PATIENTS AND METHODS: The medical records of patients with neoplasms diagnosed during the neonatal period in the previous 25 years in our hospital were retrospectively reviewed.
  • The variables analyzed were the percentage of neonatal neoplasms among the total number of cancer cases in children aged less than 14 years, their incidence among all the newborns in our hospital, sex, year of diagnosis, age at clinical diagnosis, the presence or absence of prenatal diagnosis, type of tumor (histologic diagnosis), association with syndromes or other congenital anomalies, treatment, and long-term outcome.
  • RESULTS: Of 260 neoplasms diagnosed in our unit from 1980, 16 (6.1 %) were diagnosed in the neonatal period.
  • The incidence of neonatal neoplasms was estimated to be 276.5 per million live births.
  • Histologic diagnoses were neuroblastoma (n = 5; 31.2 %), teratoma/ germ cell tumor (n = 4; 25 %), soft tissue sarcoma (one fibrosarcoma of the thigh and two hemangiopericytoma of the back and heart; 18.8 %), and one case each of mesoblastic nephroma, cerebral tumor (ependymoblastoma), melanoma (associated with giant congenital melanocytic nevi), and acute leukemia (associated with Down syndrome).
  • Treatment consisted of surgery alone (n = 10; 62.5 %) and surgery plus chemotherapy (n = 5; 31.2 %); one patient received no treatment.
  • CONCLUSIONS: The neoplasms most frequently diagnosed in the neonatal period were solid tumors, mainly neuroblastoma and teratomas/germ cell tumors; 12.5 % were associated with syndromes or congenital anomalies.
  • Most of the neoplasms responded to therapy, mainly surgery, and long-term outcome was favorable.
  • [MeSH-major] Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] An Pediatr (Barc). 2007 Jul;67(1):85-6 [17663916.001]
  • (PMID = 17194321.001).
  • [ISSN] 1695-4033
  • [Journal-full-title] Anales de pediatría (Barcelona, Spain : 2003)
  • [ISO-abbreviation] An Pediatr (Barc)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


7. Sunayama J, Sato A, Matsuda K, Tachibana K, Suzuki K, Narita Y, Shibui S, Sakurada K, Kayama T, Tomiyama A, Kitanaka C: Dual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells. Neuro Oncol; 2010 Dec;12(12):1205-19
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glioblastoma, the most intractable cerebral tumor, is highly lethal.
  • Recent studies suggest that cancer stem-like cells (CSLCs) have the capacity to repopulate tumors and mediate radio- and chemoresistance, implying that future therapies may need to turn from the elimination of rapidly dividing, but differentiated, tumor cells to specifically targeting the minority of tumor cells that repopulate the tumor.
  • Interestingly, combination treatment with rapamycin and LY294002, a phosphatidylinositol 3-kinase (PI3K) inhibitor, not only reduced the expression of NSC/progenitor markers more efficiently than single-agent treatment, but also increased the expression of βIII-tubulin, a neuronal differentiation marker.
  • These findings suggest that the PI3K/mTor signaling pathway is critical for the maintenance of glioblastoma CSLC properties, and targeting both mTor and PI3K of CSLCs may be an effective therapeutic strategy in glioblastoma.
  • [MeSH-minor] Animals. Blotting, Western. Cell Differentiation / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Chromones / pharmacology. Drug Therapy, Combination. Enzyme Inhibitors / pharmacology. Humans. Immunosuppressive Agents / pharmacology. Male. Mice. Mice, Inbred BALB C. Mice, Nude. Morpholines / pharmacology. Proto-Oncogene Proteins c-akt / metabolism. Signal Transduction. Sirolimus / pharmacology. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Glioblastoma.
  • National BioResource Project. culture/stock collections - NBRP resources .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Cancer. 2006 Jun;6(6):425-36 [16723989.001]
  • [Cites] Curr Opin Genet Dev. 2004 Feb;14(1):43-7 [15108804.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):761-5 [17151667.001]
  • [Cites] Annu Rev Med. 2007;58:267-84 [17002552.001]
  • [Cites] J Biol Chem. 2007 Jan 26;282(4):2211-20 [17132628.001]
  • [Cites] Radiother Oncol. 2007 Jan;82(1):96-104 [17161482.001]
  • [Cites] Cell. 2007 Jan 26;128(2):309-23 [17254969.001]
  • [Cites] Am J Pathol. 2007 May;170(5):1445-53 [17456751.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Jul 6;358(3):908-13 [17512905.001]
  • [Cites] J Cell Sci. 2007 Aug 1;120(Pt 15):2479-87 [17646672.001]
  • [Cites] Cancer Res. 2007 Oct 1;67(19):8980-4 [17908997.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16158-63 [17911267.001]
  • [Cites] Biochem J. 2007 Dec 15;408(3):297-315 [17850214.001]
  • [Cites] FASEB J. 2007 Dec;21(14):3777-85 [17625071.001]
  • [Cites] PLoS Med. 2008 Jan 22;5(1):e8 [18215105.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1926-33 [15143086.001]
  • [Cites] Invest New Drugs. 2004 Nov;22(4):427-35 [15292713.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7011-21 [15466194.001]
  • [Cites] J Neurosurg. 1988 Jan;68(1):1-17 [3275753.001]
  • [Cites] Nature. 1994 Feb 17;367(6464):645-8 [7509044.001]
  • [Cites] Cancer Invest. 1996;14(6):551-9 [8951359.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Nat Rev Cancer. 2005 Apr;5(4):275-84 [15803154.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3336-46 [15833867.001]
  • [Cites] Neoplasia. 2005 Apr;7(4):356-68 [15967113.001]
  • [Cites] Invest New Drugs. 2005 Aug;23(4):357-61 [16012795.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7052-8 [16103051.001]
  • [Cites] Cancer Cell. 2005 Sep;8(3):179-83 [16169463.001]
  • [Cites] Cancer Cell. 2005 Oct;8(4):323-35 [16226707.001]
  • [Cites] Cancer Cell. 2006 May;9(5):341-9 [16697955.001]
  • [Cites] Neuron. 2008 Jun 26;58(6):832-46 [18579075.001]
  • [Cites] Mol Cancer Ther. 2008 Jul;7(7):1851-63 [18606717.001]
  • [Cites] Neoplasma. 2008;55(5):369-74 [18665745.001]
  • [Cites] N Engl J Med. 2008 Jul 31;359(5):492-507 [18669428.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]
  • [Cites] Curr Opin Pharmacol. 2008 Aug;8(4):393-412 [18721898.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1129-33 [18948956.001]
  • [Cites] Cancer Sci. 2008 Oct;99(10):1871-7 [19016744.001]
  • [Cites] J Neurosci Methods. 2009 Jan 30;176(2):192-9 [19215724.001]
  • [Cites] Cell Stem Cell. 2009 Mar 6;4(3):226-35 [19265662.001]
  • [Cites] Cancer Lett. 2009 Jun 28;279(1):13-21 [19232461.001]
  • [Cites] Cell Stem Cell. 2009 Jun 5;4(6):568-80 [19497285.001]
  • [Cites] Mol Cancer Ther. 2009 Aug;8(8):2204-10 [19671762.001]
  • [Cites] Brain Res. 2008 Nov 6;1239:216-25 [18804099.001]
  • [Cites] Cell Stem Cell. 2009 Nov 6;5(5):504-14 [19896441.001]
  • [Cites] J Neurosurg. 2000 Aug;93(2):201-7 [10930004.001]
  • [Cites] Blood. 2001 Jul 1;98(1):174-80 [11418477.001]
  • [Cites] Glia. 2002 Sep;39(3):193-206 [12203386.001]
  • [Cites] Oncogene. 2002 Sep 26;21(43):6587-97 [12242656.001]
  • [Cites] Curr Treat Options Oncol. 2002 Dec;3(6):509-24 [12392640.001]
  • [Cites] Trends Cell Biol. 2003 Feb;13(2):79-85 [12559758.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15178-83 [14645703.001]
  • [Cites] Cancer. 2004 Feb 1;100(3):605-11 [14745879.001]
  • [Cites] N Engl J Med. 2006 Sep 21;355(12):1253-61 [16990388.001]
  • (PMID = 20861085.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromones; 0 / Enzyme Inhibitors; 0 / Imidazoles; 0 / Immunosuppressive Agents; 0 / Morpholines; 0 / Quinolines; 154447-36-6 / 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.1.137 / Phosphatidylinositol 3-Kinase; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; RUJ6Z9Y0DT / dactolisib; W36ZG6FT64 / Sirolimus
  • [Other-IDs] NLM/ PMC3018946
  •  go-up   go-down


8. Fiorillo A, Maggi G, Martone A, Migliorati R, D'Amore R, Alfieri E, Greco N, Cirillo S, Marano I: Shunt-related abdominal metastases in an infant with medulloblastoma: long-term remission by systemic chemotherapy and surgery. J Neurooncol; 2001 May;52(3):273-6
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Shunt-related abdominal metastases in an infant with medulloblastoma: long-term remission by systemic chemotherapy and surgery.
  • This is the first reported case of long remission of abdominal metastases spread through a ventriculo-peritoneal shunt in an infant diagnosed, four years ago, at age 1 year and 10 months, to have cerebral medulloblastoma.
  • Two years later, while in second complete remission of his cerebral tumor, he showed abdominal metastases, successfully treated by platinum based chemotherapy and surgery.
  • This unusual favorable outcome can be explained by an extreme responsiveness of the tumor, unprotected by the blood brain barrier, to systemic chemotherapy, particularly to doxorubicin administration.
  • Searching for new tools, such as entrapment of doxorubicin in liposomes, able to overcome the blood-brain barrier and to expose brain tumors to effective drugs, probably represents the best choice for future treatment strategies of CNS tumors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cerebellar Neoplasms / pathology. Medulloblastoma / secondary. Peritoneal Neoplasms / secondary. Ventriculoperitoneal Shunt / adverse effects
  • [MeSH-minor] Carboplatin / administration & dosage. Carmustine / administration & dosage. Combined Modality Therapy. Cranial Irradiation. Craniotomy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Humans. Hydrocephalus / surgery. Hydrocephalus / therapy. Hydroxyurea / administration & dosage. Infant. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local / drug therapy. Pelvic Neoplasms / drug therapy. Pelvic Neoplasms / surgery. Remission Induction

  • Genetic Alliance. consumer health - Medulloblastoma.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Childs Nerv Syst. 1988 Dec;4(6):321-4 [3245941.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):832-45 [10071274.001]
  • [Cites] Childs Nerv Syst. 1998 Jan-Feb;14(1-2):2-5 [9548331.001]
  • [Cites] J Neurosurg. 1991 Jun;74(6):872-7 [2033446.001]
  • [Cites] Pediatr Neurosurg. 1993 Jul-Aug;19(4):171-9 [8329301.001]
  • [Cites] Pediatr Neurosurg. 1994;20(1):19-29 [8142278.001]
  • [Cites] Neurosurgery. 1996 Feb;38(2):265-71 [8869053.001]
  • [Cites] Childs Nerv Syst. 1998 Jan-Feb;14(1-2):10-4 [9548333.001]
  • [Cites] Nucl Med Commun. 1997 Jan;18(1):17-23 [9061696.001]
  • [Cites] Surg Neurol. 1993 Nov;40(5):403-10 [8211658.001]
  • [Cites] Bone Marrow Transplant. 1992 Apr;9(4):227-33 [1534708.001]
  • [Cites] J Neurosurg. 1995 Dec;83(6):1029-37 [7490617.001]
  • [Cites] J Neurooncol. 1997 Apr;32(2):149-54 [9120544.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1977 Sep-Oct;2(9-10):833-41 [597384.001]
  • [Cites] Childs Nerv Syst. 1997 Jul;13(7):388-96 [9298275.001]
  • [Cites] Am Surg. 1988 Jan;54(1):50-5 [3276260.001]
  • [Cites] N Engl J Med. 1993 Jun 17;328(24):1725-31 [8388548.001]
  • [Cites] Cancer. 1996 Aug 1;78(3):532-41 [8697401.001]
  • [Cites] Childs Nerv Syst. 1998 Jun;14(6):227-9 [9694333.001]
  • [Cites] J Neurooncol. 1996 Jul;29(1):69-74 [8817417.001]
  • [Cites] J Neurooncol. 1992 Jun;13(2):151-5 [1432032.001]
  • [Cites] Childs Nerv Syst. 1994 Jan;10(1):2-12 [8194058.001]
  • [Cites] Childs Nerv Syst. 1995 Oct;11(10):574-8 [8556723.001]
  • (PMID = 11519858.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; U68WG3173Y / Carmustine; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


9. Zanetta F, Di Dio G, Savastio S, Saccagno A, Petri A, Bellone S, Maghnie M, Bona G: [Germinoma: a rare cerebral tumor causing central diabetes insipidus in childhood]. Minerva Pediatr; 2008 Feb;60(1):129-33
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Germinoma: a rare cerebral tumor causing central diabetes insipidus in childhood].
  • Germinoma represents 7.8% of cerebral tumors in pediatric age and 50-65% of germ cell cerebral tumors.
  • Clinical presentation depends on tumor localization.
  • Pineal lesions generally determine symptoms due to the compression of cerebral structures, causing Parinaud syndrome, while hypothalamic lesions are often characterized by diabetes insipidus, hypopituitarism and visual defects.
  • The patient started therapy with desmopressin (Minirin) with good hydro-electrolytic balance.
  • [MeSH-major] Diabetes Insipidus / diagnosis. Diabetes Insipidus / etiology. Germinoma / complications. Germinoma / diagnosis. Pituitary Neoplasms / complications. Pituitary Neoplasms / diagnosis
  • [MeSH-minor] Antidiuretic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Deamino Arginine Vasopressin / therapeutic use. Diagnosis, Differential. Drug Therapy, Combination. Humans. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Diabetes.
  • Genetic Alliance. consumer health - Diabetes Insipidus.
  • Genetic Alliance. consumer health - Germinoma.
  • MedlinePlus Health Information. consumer health - Diabetes Insipidus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18277371.001).
  • [ISSN] 0026-4946
  • [Journal-full-title] Minerva pediatrica
  • [ISO-abbreviation] Minerva Pediatr.
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antidiuretic Agents; ENR1LLB0FP / Deamino Arginine Vasopressin
  •  go-up   go-down


10. Patriarca F, Zaja F, Silvestri F, Sperotto A, Scalise A, Gigli G, Fanin R: Meningeal and cerebral involvement in multiple myeloma patients. Ann Hematol; 2001 Dec;80(12):758-62
Hazardous Substances Data Bank. PREDNISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningeal and cerebral involvement in multiple myeloma patients.
  • Cerebral involvement is an unusual complication in multiple myeloma: herein four patients who presented myelomatous meningitis with multiple intraparenchymal lesions or a localized cerebral plasmacytoma are described.
  • Two of these patients relapsed with meningeal involvement and a very limited disease outside the central nervous system after an initial complete remission obtained with induction chemotherapy.
  • In the other two cases, the cerebral tumor appeared during first-line treatment.
  • Different modalities of treatment were used, including intrathecal chemotherapy, cranial irradiation, and systemic chemotherapy with high-dose methotrexate and cytarabine, achieving improvement of neurological symptoms in three of four patients.
  • [MeSH-major] Brain Neoplasms / complications. Meningitis / etiology. Multiple Myeloma / complications. Plasmacytoma / complications
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Cerebrospinal Fluid / cytology. Cerebrospinal Fluid Proteins / analysis. Combined Modality Therapy. Fatal Outcome. Female. Glucocorticoids / therapeutic use. Humans. Immunoglobulin Light Chains / analysis. Immunoglobulin kappa-Chains / analysis. Magnetic Resonance Imaging. Middle Aged. Prednisone / therapeutic use. Radiotherapy. Recurrence. Remission Induction

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Meningitis.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11797120.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cerebrospinal Fluid Proteins; 0 / Glucocorticoids; 0 / Immunoglobulin Light Chains; 0 / Immunoglobulin kappa-Chains; VB0R961HZT / Prednisone
  •  go-up   go-down


11. Gautschi OP, Cadosch D, Collen TD, Land M, Hoederath P, Hildebrandt G, Fournier JY, Hundsberger T: [Glioblastoma multiforme--new hope due to modern therapeutical approaches]. Praxis (Bern 1994); 2010 Mar 3;99(5):295-308
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glioblastoma multiforme (GBM) is the most frequently encountered malignant cerebral tumor.
  • Despite significant improvements in the treatment of GBM, this disease remains associated with a high morbidity and mortality, with more than half of all affected patients dying within the first year after diagnosis.
  • GBM can be identified by means of cerebral imaging modalities and subsequently confirmed histopathologically through biopsy or resection.
  • At present, surgical resection followed by radiotherapy with concomitant chemotherapy with temozolomide and subsequent adjuvant chemotherapy with temozolomide is considered the standard therapy for patients with GBM.
  • [MeSH-major] Glioblastoma / therapy
  • [MeSH-minor] Algorithms. Antineoplastic Agents, Alkylating / therapeutic use. Chemotherapy, Adjuvant. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Humans. Prognosis. Time Factors

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20205087.001).
  • [ISSN] 1661-8157
  • [Journal-full-title] Praxis
  • [ISO-abbreviation] Praxis (Bern 1994)
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  • [Number-of-references] 50
  •  go-up   go-down


12. Gutenberg A, Schulten HJ, Gunawan B, Ludwig HC, Brück W, Larsen J, Rohde V: CNS tumor 22 years after spinal neuroblastoma IV: diagnostic dilemma between recurrence and secondary malignancy. Pediatr Neurosurg; 2009;45(1):61-8
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CNS tumor 22 years after spinal neuroblastoma IV: diagnostic dilemma between recurrence and secondary malignancy.
  • We present the very unusual case of a young woman suffering from a brain tumor 22 years after a stage IV spinal neuroblastoma as an infant, demonstrating the difficulties of differentiating late neuroblastoma relapse from secondary supratentorial primitive neuroectodermal tumor (sPNET).
  • Lacking specific immunohistochemical features, the first cerebral tumor at the age of 21 was regarded as sPNET, and we pursued a therapeutic approach consisting of neurosurgical resection as well as irradiation and high-dose alkylator-based chemotherapy according to the HIT2000 protocol.
  • [MeSH-major] Brain Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Neoplasms, Second Primary / pathology. Neuroblastoma / pathology. Spinal Neoplasms / pathology
  • [MeSH-minor] Adult. DNA, Neoplasm / genetics. Diagnosis, Differential. Female. Genetic Markers. Humans. Immunohistochemistry. Infant. Magnetic Resonance Imaging. Neoplasm Staging. Time Factors

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19258732.001).
  • [ISSN] 1423-0305
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Genetic Markers
  •  go-up   go-down


13. Hyder DJ, Sung L, Pollack IF, Gilles FH, Yates AJ, Davis RL, Boyett JM, Finlay JL: Anaplastic mixed gliomas and anaplastic oligodendroglioma in children: results from the CCG 945 experience. J Neurooncol; 2007 May;83(1):1-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To review interpathologist diagnosis variability and survival of children treated for either anaplastic mixed glioma (AMG) or anaplastic oligodendroglioma (AO) with surgery, irradiation and chemotherapy.
  • PATIENTS AND METHODS: Two hundred and fifty patients with an institutional diagnosis of malignant glioma were enrolled on Children's Cancer Group CCG-945 between 1985 and 1991, and administered vincristine during involved field radiotherapy, then six cycles of prednisone, lomustine and, vincristine; or two cycles of "eight-drugs-in-one-day" (8-in-1) chemotherapy then involved-field radiotherapy followed by six cycles of 8-in-1 chemotherapy.
  • Complete resection and cerebral tumor location was associated with better overall survival (OS) in patients with institutional diagnoses of AMG.
  • CONCLUSION: Diagnosis of these tumors is challenging, with only 35% of institutional diagnoses confirmed for AMG and 25% for AO, and survival among children with these tumors is poor, despite intensive therapy.
  • This suggests reliable diagnostic markers and new therapeutic approaches are needed.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Central Nervous System Neoplasms / therapy. Glioma / diagnosis. Glioma / therapy. Oligodendroglioma / diagnosis. Oligodendroglioma / therapy
  • [MeSH-minor] Adolescent. Astrocytoma / diagnosis. Astrocytoma / therapy. Brain Neoplasms / diagnosis. Brain Neoplasms / therapy. Child. Child, Preschool. Cohort Studies. Drug Therapy. Female. Humans. Infant. Male. Neurosurgical Procedures. Radiotherapy. Spinal Cord Neoplasms / diagnosis. Spinal Cord Neoplasms / therapy. Survival Analysis

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1998 Jul;89(1):52-9 [9647172.001]
  • [Cites] Hepatology. 1991 Nov;14(5):751-5 [1937381.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1243-52 [12973849.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 Oct;56(10):1098-104 [9329453.001]
  • [Cites] Childs Nerv Syst. 1999 Nov;15(11-12):786-8 [10603023.001]
  • [Cites] J Neurooncol. 1994;21(3):255-65 [7699420.001]
  • [Cites] Surg Neurol. 2003 Nov;60(5):443-56 [14572971.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):251-5 [12525516.001]
  • [Cites] J Neurosurg. 1995 Apr;82(4):536-47 [7897512.001]
  • [Cites] J Neurooncol. 2003 May;63(1):49-54 [12814254.001]
  • [Cites] J Chronic Dis. 1967 Aug;20(8):637-48 [4860352.001]
  • [Cites] J Neurooncol. 1988;6(1):9-23 [3294353.001]
  • [Cites] Neuro Oncol. 2003 Jul;5(3):197-207 [12816726.001]
  • [Cites] Neurosurgery. 2002 Jun;50(6):1238-44; discussion 1244-5 [12015841.001]
  • [Cites] Biometrics. 1977 Mar;33(1):159-74 [843571.001]
  • [Cites] Pediatr Neurosurg. 2003 Sep;39(3):114-21 [12876389.001]
  • [Cites] Curr Treat Options Oncol. 2000 Dec;1(5):459-68 [12057153.001]
  • [Cites] J Neuropathol Exp Neurol. 1994 Nov;53(6):559-71 [7964897.001]
  • [Cites] N Engl J Med. 2002 Feb 7;346(6):420-7 [11832530.001]
  • [Cites] J Acquir Immune Defic Syndr. 1990;3 Suppl 2:S120-3 [2231292.001]
  • [Cites] J Neuropathol Exp Neurol. 1995 Jan;54(1):91-5 [7815084.001]
  • [Cites] J Neurosurg. 1998 Feb;88(2):215-20 [9452226.001]
  • (PMID = 17252186.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


14. De Tommasi A, De Tommasi C, Occhiogrosso G, Cimmino A, Parisi M, Sanguedolce F, Ciappetta P: Primary intramedullary primitive neuroectodermal tumor (PNET)--case report and review of the literature. Eur J Neurol; 2006 Mar;13(3):240-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary intramedullary primitive neuroectodermal tumor (PNET)--case report and review of the literature.
  • The optimal treatment for these malignant tumors is not yet clear, although, over the years, radiotherapy has been considered the best treatment for spinal PNETs.
  • The described case is that of a 38-year-old man with a primary intra-extramedullary PNET, treated by laminectomy, open biopsy and chemotherapy.
  • The patient, 18 months after the onset of his symptomatology, died without cerebral tumor involvement.
  • [MeSH-major] Brain Neoplasms. Laminectomy / methods. Neuroectodermal Tumors, Primitive

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16618339.001).
  • [ISSN] 1351-5101
  • [Journal-full-title] European journal of neurology
  • [ISO-abbreviation] Eur. J. Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 25
  •  go-up   go-down


15. Serinet MO, Jacquemin E, Habes D, Debray D, Fabre M, Bernard O: Anti-CD20 monoclonal antibody (Rituximab) treatment for Epstein-Barr virus-associated, B-cell lymphoproliferative disease in pediatric liver transplant recipients. J Pediatr Gastroenterol Nutr; 2002 Apr;34(4):389-93
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-CD20 monoclonal antibody (Rituximab) treatment for Epstein-Barr virus-associated, B-cell lymphoproliferative disease in pediatric liver transplant recipients.
  • OBJECTIVES: Anti-B-cell immunotherapy has been used with success in adults with posttransplant B-cell lymphoproliferative disease (PTLD), but such treatment has rarely been reported in children.
  • We report the outcome of anti-CD20 antibody (rituximab) therapy for Epstein-Barr virus (EBV)-associated PTLD in six pediatric liver transplant recipients.
  • Anti-CD20 therapy was associated with withdrawal of tacrolimus or ciclosporine therapy in all patients.
  • RESULTS: Rituximab treatment was associated with decreased EBV load, disappearance of abnormal serum immunoglobulin concentration, and disappearance of tumoral masses, which occurred 1 to 2.5 months after treatment onset.
  • Despite rituximab therapy, one patient was diagnosed subsequently with a cerebral tumor.
  • Five patients experienced acute liver graft rejection episodes within 10 days to 2.5 months after beginning treatment.
  • In these patients, immunosuppression was reintroduced, but three children experienced fatal chronic rejection, whereas two experienced complete tumor remission.
  • CONCLUSIONS: Rituximab therapy is an interesting approach for children with early EBV-associated PTLD after liver transplantation.
  • It does not prevent cerebral localization, and rapid resumption of immunosuppression may be advisable to prevent lethal chronic liver graft rejection.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. B-Lymphocytes / immunology. Epstein-Barr Virus Infections / complications. Liver Transplantation / adverse effects. Lymphoproliferative Disorders / drug therapy

  • Genetic Alliance. consumer health - Liver Disease.
  • Genetic Alliance. consumer health - Liver Transplant.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Pediatr Gastroenterol Nutr. 2002 Apr;34(4):359-61 [11930089.001]
  • (PMID = 11930095.001).
  • [ISSN] 0277-2116
  • [Journal-full-title] Journal of pediatric gastroenterology and nutrition
  • [ISO-abbreviation] J. Pediatr. Gastroenterol. Nutr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


16. Witwer BP, Moftakhar R, Hasan KM, Deshmukh P, Haughton V, Field A, Arfanakis K, Noyes J, Moritz CH, Meyerand ME, Rowley HA, Alexander AL, Badie B: Diffusion-tensor imaging of white matter tracts in patients with cerebral neoplasm. J Neurosurg; 2002 Sep;97(3):568-75
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffusion-tensor imaging of white matter tracts in patients with cerebral neoplasm.
  • OBJECT: Preserving vital cerebral function while maximizing tumor resection is a principal goal in surgical neurooncology.
  • Although functional magnetic resonance imaging has been useful in the localization of eloquent cerebral cortex, this method does not provide information about the white matter tracts that may be involved in invasive, intrinsic brain tumors.
  • Recently, diffusion-tensor (DT) imaging techniques have been used to map white matter tracts in the normal brain.
  • The aim of this study was to demonstrate the role of DT imaging in preoperative mapping of white matter tracts in relation to cerebral neoplasms.
  • METHODS: Nine patients with brain malignancies (one pilocytic astrocytoma, five oligodendrogliomas, one low-grade oligoastrocytoma, one Grade 4 astrocytoma, and one metastatic adenocarcinoma) underwent DT imaging examinations prior to tumor excision.
  • Depending on the tumor type and location, evidence of white matter tract edema (two patients), infiltration (two patients), displacement (five patients), and disruption (two patients) could be assessed with the aid of DT imaging in each case.
  • The authors' experience with DT imaging indicates that anatomically intact fibers may be present in abnormal-appearing areas of the brain.
  • [MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / surgery. Magnetic Resonance Imaging / methods. Nerve Fibers / pathology. Oligodendroglioma / pathology. Oligodendroglioma / surgery

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12296640.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Grant] United States / NIMH NIH HHS / MH / R01 MH62015
  • [Publication-type] Case Reports; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


17. Alexiou GA, Moschovi M, Stefanaki K, Prodromou C, Sfakianos G, Prodromou N: Malignant progression of a pleomorphic xanthoastrocytoma in a child. Neuropediatrics; 2010 Aug;41(2):69-71
Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pleomorphic xanthoastrocytoma (PXA) is a recently recognized rare cerebral neoplasm that predominantly affects young patients.
  • 1 year later follow-up magnetic resonance imaging (MRI) revealed tumor relapse.
  • The patient received radiotherapy and 9 months later on follow-up MRI a new tumor recurrence was noted.
  • A third craniotomy was performed and the tumor removed.
  • The patient was referred to the oncology department and received chemotherapy with temozolamide.
  • 8 months later the patient was stable without tumor recurrence.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Brain Neoplasms / physiopathology. Glioblastoma / diagnosis
  • [MeSH-minor] Child, Preschool. Disease Progression. Gadolinium. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Pleomorphic xanthoastrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag KG Stuttgart.New York.
  • (PMID = 20799153.001).
  • [ISSN] 1439-1899
  • [Journal-full-title] Neuropediatrics
  • [ISO-abbreviation] Neuropediatrics
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] AU0V1LM3JT / Gadolinium
  •  go-up   go-down


18. Sakurai T, Tanaka Y, Koumura A, Hayashi Y, Kimura A, Hozumi I, Yoneda M, Inuzuka T: [Case report of a patient with Hashimoto's encephalopathy associated with Basedow's disease mimicking Creutzfeldt-Jakob disease]. Brain Nerve; 2008 May;60(5):559-65
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Brain MRI showed cerebral atrophy, and brain 99mTc-ECD-SPECT images demonstrated an overall decrease in the accumulation of 99mTc in the cerebrum.
  • We initiated treatment for hyperthyroidism with thiamazole and lugol, but this did not regain consciousness.
  • Because she had anti-thyroid antibody was observed, we considered a differential diagnosis of Hashimoto's encephalopathy and, in fact, methylprednisolone pulse therapy alleviated her symptoms and normalized the EEG findings.
  • [MeSH-minor] Aged. Autoantibodies / blood. Biomarkers / blood. Biomarkers, Tumor / immunology. Creutzfeldt-Jakob Syndrome. DNA-Binding Proteins / immunology. Diagnosis, Differential. Electroencephalography. Female. Humans. Magnetic Resonance Imaging. Methylprednisolone / administration & dosage. Phosphopyruvate Hydratase / immunology. Pulse Therapy, Drug. Tomography, Emission-Computed, Single-Photon. Tumor Suppressor Proteins / immunology

  • Genetic Alliance. consumer health - Creutzfeldt-Jakob Disease.
  • Genetic Alliance. consumer health - Hashimoto's Disease.
  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18516979.001).
  • [ISSN] 1881-6096
  • [Journal-full-title] Brain and nerve = Shinkei kenkyū no shinpo
  • [ISO-abbreviation] Brain Nerve
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Tumor Suppressor Proteins; EC 4.2.1.11 / ENO1 protein, human; EC 4.2.1.11 / Phosphopyruvate Hydratase; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


19. Birbilis TA, Matis GK, Eleftheriadis SG, Theodoropoulou EN, Sivridis E: Spinal metastasis of glioblastoma multiforme: an uncommon suspect? Spine (Phila Pa 1976); 2010 Apr 1;35(7):E264-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SUMMARY OF BACKGROUND DATA: GBM constitutes the most common adult malignant brain tumor with poor prognosis.
  • However, recent advances in cancer treatment prolongate survival and provide adequate time for these metastases to give clinical symptoms.
  • METHODS: We hereby present a case of a 57-year-old woman with a history of pineal GBM treated by stereotactic biopsy, chemotherapy, and radiotherapy, readmitted 38 months later due to gait disturbance, spastic paraparesis, edema of lower limbs, bilateral positive Babinski response, and loss of bladder control.
  • No further treatment was given, and the patient died 2 months after the diagnosis of the spinal metastasis.
  • CONCLUSION: Spinal metastases should be commonly suspected in patients with a history of intracranial GBM who complain about symptoms not explained by the primary lesion.Glioblastoma multiforme (GBM) was first described by Rudolph Virchow in 1863 and represents the most common and most malignant tumor of the cerebral hemispheres, usually arising between the ages of 40 and 60 years.
  • [MeSH-major] Brain Neoplasms / pathology. Glioblastoma / secondary. Pineal Gland / pathology. Spinal Neoplasms / secondary

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20195200.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Morawiec-Bajda A, Wasilewski B: [Myogenic vestibular evoked potentials used to objective estimation of effectiveness of central action drugs]. Otolaryngol Pol; 2000;54(3):327-36
Hazardous Substances Data Bank. PICROTOXIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Myogenic vestibular evoked potentials used to objective estimation of effectiveness of central action drugs].
  • In this paper possibility of employing vestibular evoked myogenic potentials (VEMPs) was evaluated to following efficacy of drug effect in patients with central and peripheral vestibular disorders of various aetiologies.
  • Treatment concerned 23 ills that is 20 women and 3 men in age from 20 to 68 years, average age being 46,82 years.
  • Patients with tumor of ponto-cerebellaris angle or VIII nerve were excluded.
  • Registration of VEMPs was done in all patients treated before starting and after stopping therapy.
  • After using of Cerebrum comp. improvement of vestibulo-spinal reflex function was affirmed in the form of shorted latencies and higher amplitudes of VEMPs in the most patients.
  • Using sublingually of Vertigoheel distinct greater amplitudes were observed in significant numbers of patients after therapy.
  • [MeSH-major] Evoked Potentials / physiology. Meniere Disease / drug therapy. Meniere Disease / physiopathology. Vestibule, Labyrinth / physiopathology
  • [MeSH-minor] Adult. Aged. Central Nervous System Agents / therapeutic use. Drug Combinations. Female. Humans. Male. Middle Aged. Minerals / therapeutic use. Phytotherapy. Picrotoxin / therapeutic use. Plant Extracts / therapeutic use. Plants, Medicinal / therapeutic use. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Meniere's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10917061.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] POLAND
  • [Chemical-registry-number] 0 / Central Nervous System Agents; 0 / Drug Combinations; 0 / Minerals; 0 / Plant Extracts; 0 / Vertigoheel; 124-87-8 / Picrotoxin
  •  go-up   go-down


21. Rorke-Adams LB, Portnoy H: Long-term survival of an infant with gliomatosis cerebelli. J Neurosurg Pediatr; 2008 Nov;2(5):346-50

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gliomatosis cerebri is an uncommon but well-established central nervous system neoplasm that occurs primarily in adults.
  • Although the neoplastic process typically arises in the cerebrum, it often spreads to brainstem, cerebellum, or even the spinal cord.
  • In this report the authors document the surgical treatment of a 13-month-old boy whose tumor arose in the cerebellum and over time extended to the thalamus where its growth halted at age 3 years and 10 months.
  • Aside from 2 partial resections the patient underwent neither radiotherapy nor chemotherapy.
  • [MeSH-major] Cerebellar Neoplasms / pathology. Cerebellar Neoplasms / surgery. Neoplasms, Neuroepithelial / pathology. Neoplasms, Neuroepithelial / surgery
  • [MeSH-minor] Adult. Disease-Free Survival. Humans. Infant. Male. Neoplasm Invasiveness. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18976105.001).
  • [ISSN] 1933-0707
  • [Journal-full-title] Journal of neurosurgery. Pediatrics
  • [ISO-abbreviation] J Neurosurg Pediatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Yumura Y, Chiba K, Okada Y, Hirokawa M: [Brain metastasis of bladder carcinoma after total cystectomy: a case report]. Hinyokika Kiyo; 2000 Nov;46(11):807-9
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two courses of adjuvant chemotherapy with CDDP and MTX were added.
  • Brain MRI examination revealed a solid tumor, 4 x 4 x 3 cm in size, in the right frontal lobe of the cerebrum.
  • She underwent surgical resection of the tumor and subsequent irradiation to right frontal lobe in the cerebrum.
  • [MeSH-major] Brain Neoplasms / secondary. Carcinoma, Transitional Cell / secondary. Cystectomy. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Female. Humans. Methotrexate / administration & dosage. Treatment Outcome. Ureterostomy

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11193302.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


23. Watanabe W, Kuwabara R, Nakahara T, Hamasaki O, Sakamoto I, Okada K, Minamoto A, Mishima HK: Severe ocular and orbital toxicity after intracarotid injection of carboplatin for recurrent glioblastomas. Graefes Arch Clin Exp Ophthalmol; 2002 Dec;240(12):1033-5
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Glioblastoma is a malignant tumor that occurs in the cerebrum during adulthood.
  • With current treatment regimens including combined surgery, radiation and chemotherapy, the average life expectancy of the patients is limited to approximately 1 year.
  • Therefore, patients with glioblastoma sometimes have intracarotid injection of carcinostatics added to the treatment regimen.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Blindness / chemically induced. Brain Neoplasms / drug therapy. Carboplatin / adverse effects. Glioblastoma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Orbital Diseases / chemically induced

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12483326.001).
  • [ISSN] 0721-832X
  • [Journal-full-title] Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv für klinische und experimentelle Ophthalmologie
  • [ISO-abbreviation] Graefes Arch. Clin. Exp. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin
  •  go-up   go-down


24. Sharma RR, Pawar SJ, Dev EJ, Ebenezer S, Mahapatra AK: Hypersensitivity to glucocorticoids in patients with raised ICP : report of two cases. Neurol India; 2001 Dec;49(4):404-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Corticosteroids are widely used in patients with raised intracranial pressure associated with cerebral neoplasms, cerebral vascular malformations, cerebral ischaemia and benign intracranial hypertension.
  • Authors report two patients with raised intracranial pressure who developed steroid hypersensitivity.
  • [MeSH-major] Drug Hypersensitivity / etiology. Glucocorticoids / adverse effects. Intracranial Hypertension / drug therapy

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Steroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11799418.001).
  • [ISSN] 0028-3886
  • [Journal-full-title] Neurology India
  • [ISO-abbreviation] Neurol India
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Glucocorticoids
  • [Number-of-references] 11
  •  go-up   go-down


25. Avila EK, Graber J: Seizures and epilepsy in cancer patients. Curr Neurol Neurosci Rep; 2010 Jan;10(1):60-7
MedlinePlus Health Information. consumer health - Seizures.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, seizures as a result of cancer treatment, metabolic causes, or paraneoplastic diseases may occur in patients with systemic cancer, even in the absence of a cerebral lesion.
  • The etiology of seizures in brain tumor patients includes primary cerebral neoplasms and metastatic brain lesions.
  • The treatment for seizures in this population is multifaceted and involves surgery, radiation, chemotherapy, and antiepileptic drugs.
  • All treatments have potential adverse effects, especially when combined.
  • The treatment for brain tumor-associated seizures and epilepsy almost always is geared toward treating the tumor, but subsequent treatment of seizures often is necessary.
  • A pragmatic approach to this problem is essential to mitigate potential complications from treatment.
  • [MeSH-major] Brain Neoplasms / complications. Epilepsy / etiology. Seizures / etiology
  • [MeSH-minor] Anticonvulsants / therapeutic use. Humans

  • Genetic Alliance. consumer health - Epilepsy.
  • Genetic Alliance. consumer health - Seizures.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Epilepsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Neurophysiol. 2004 Sep-Oct;21(5):332-40 [15592007.001]
  • [Cites] Lancet Neurol. 2007 May;6(5):421-30 [17434097.001]
  • [Cites] Epilepsia. 1990;31 Suppl 3:S37-44 [2121472.001]
  • [Cites] Mayo Clin Proc. 1996 Jun;71(6):576-86 [8642887.001]
  • [Cites] Epilepsia. 2003 Jun;44(6):822-30 [12790896.001]
  • [Cites] J Neurol. 2009 Sep;256(9):1519-26 [19434440.001]
  • [Cites] J Neurooncol. 2009 Jul;93(3):349-54 [19169651.001]
  • [Cites] Arch Neurol. 2004 Mar;61(3):362-5 [15023812.001]
  • [Cites] Ann Oncol. 2003 Dec;14 (12 ):1722-6 [14630675.001]
  • [Cites] Epilepsy Res. 1994 Jun;18(2):155-66 [7957038.001]
  • [Cites] Acta Neurol Scand. 2009 Sep;120(3):210-2 [19719809.001]
  • [Cites] Neurology. 1993 Aug;43(8):1599-601 [8351019.001]
  • [Cites] Curr Oncol Rep. 2008 Jan;10(1):63-71 [18366962.001]
  • [Cites] J Neurooncol. 2008 Nov;90(2):217-21 [18612799.001]
  • [Cites] Neurology. 2002 Nov 12;59(9 Suppl 5):S21-6 [12428028.001]
  • [Cites] Epilepsy Res. 2009 Jul;85(1):31-45 [19369037.001]
  • [Cites] Arch Neurol. 2001 Aug;58(8):1310 [11493178.001]
  • [Cites] Brain. 2011 Oct;134(Pt 10):2795-7 [22073412.001]
  • [Cites] Stereotact Funct Neurosurg. 1996-1997;67(3-4):169-82 [9311074.001]
  • [Cites] Can J Neurol Sci. 1996 May;23(2):128-31 [8738926.001]
  • [Cites] J Neurooncol. 2008 Jan;86(1):61-70 [17598071.001]
  • [Cites] Neurology. 2006 Apr 25;66(8):1261-3 [16636249.001]
  • [Cites] Neurology. 2000 May 23;54(10):1886-93 [10822423.001]
  • [Cites] Neurol Sci. 2009 Aug;30(4):353-9 [19415165.001]
  • [Cites] Clin Ther. 2008 Aug;30(8):1385-407 [18803983.001]
  • [Cites] Epilepsia. 2001 Apr;42(4):515-24 [11440347.001]
  • [Cites] J Clin Oncol. 1997 Sep;15(9):3129-40 [9294476.001]
  • [Cites] Epileptic Disord. 2005 Sep;7(3):253-96 [16162436.001]
  • [Cites] J Exp Clin Cancer Res. 2009 May 06;28:60 [19419544.001]
  • [Cites] N Engl J Med. 2008 Oct 23;359(17):1853 [18946077.001]
  • [Cites] Clin Neurol Neurosurg. 2009 Feb;111(2):171-3 [18977587.001]
  • [Cites] Neurosurg Rev. 2009 Jul;32(3):275-84; discussion 284-6 [19205766.001]
  • [Cites] Ann Oncol. 2003 Dec;14 (12 ):1715-21 [14630674.001]
  • [Cites] N Engl J Med. 1998 Sep 17;339(12):792-8 [9738086.001]
  • [Cites] Neurologist. 2008 Nov;14(6 Suppl 1):S44-54 [19225370.001]
  • [Cites] Ann Neurol. 1992 Mar;31(3):268-73 [1637135.001]
  • [Cites] J Neurooncol. 2007 Sep;84(3):293-6 [17431542.001]
  • [Cites] Curr Opin Neurol. 1996 Dec;9(6):424-8 [9007399.001]
  • [Cites] Epilepsia. 1993 May-Jun;34(3):453-68 [8504780.001]
  • [Cites] J Neurooncol. 2000 Apr;47(2):167-74 [10982159.001]
  • [Cites] J Neurooncol. 2007 Feb;81(3):279-85 [16944312.001]
  • [Cites] J Neurol Sci. 1999 Jun 15;166(1):1-15 [10465493.001]
  • [Cites] Neurology. 2008 Aug 26;71(9):665-9 [18725591.001]
  • [Cites] Neurology. 2000 Jan 25;54(2):340-5 [10668693.001]
  • [Cites] Neurology. 1996 Jul;47(1):83-9 [8710130.001]
  • [Cites] Neurosurg Focus. 2005 Jun 15;18(6A):E5 [16048291.001]
  • [Cites] Eur J Neurol. 2005 Sep;12(9):685-90 [16128869.001]
  • (PMID = 20425228.001).
  • [ISSN] 1534-6293
  • [Journal-full-title] Current neurology and neuroscience reports
  • [ISO-abbreviation] Curr Neurol Neurosci Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants
  • [Number-of-references] 50
  •  go-up   go-down


26. Borchers M, von der Mülbe B, Teikemeier F, Theegarten D: [Pulmonary nocardiasis with abscesses spreading to cerebrum, cerebellum and orbits]. Dtsch Med Wochenschr; 2006 May 12;131(19):1085-8
Hazardous Substances Data Bank. TRIMETHOPRIM/SULFAMETHOXAZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pulmonary nocardiasis with abscesses spreading to cerebrum, cerebellum and orbits].
  • [Transliterated title] Pulmonale Nokardiose mit abszedierenden zerebralen, zerebellären und orbitalen Streuherden.
  • INVESTIGATIONS: Computed tomography revealed a left apical lung abscess.
  • In the further course of the disease magnetic resonance imaging of the head demonstrated multiple abscesses in both cerebral hemispheres and an abscess, 3.4 cm in diameter, in the right side of the cerebellum, as well as a intra-orbital tumor on the right.
  • TREATMENT AND COURSE: Over 3 weeks antimicrobial treatment was given with imipenem and amikacin, followed by oral cotrimoxazole for 12 months.
  • As the resistance pattern of N. farcinica to antibiotics varies, early treatment is essential with antibiotics to which it is sensitive.
  • [MeSH-minor] Aged. Amikacin / therapeutic use. Anti-Bacterial Agents / therapeutic use. Biopsy, Needle / methods. Diagnosis, Differential. Drug Therapy, Combination. Female. Humans. Imipenem / therapeutic use. Magnetic Resonance Imaging. Tomography, X-Ray Computed. Treatment Outcome. Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use

  • MedlinePlus Health Information. consumer health - Cerebellar Disorders.
  • Hazardous Substances Data Bank. AMIKACIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16685629.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 71OTZ9ZE0A / Imipenem; 8064-90-2 / Trimethoprim, Sulfamethoxazole Drug Combination; 84319SGC3C / Amikacin
  •  go-up   go-down


27. Erşahin M, Toklu HZ, Erzik C, Cetinel S, Akakin D, Velioğlu-Oğünç A, Tetik S, Ozdemir ZN, Sener G, Yeğen BC: The anti-inflammatory and neuroprotective effects of ghrelin in subarachnoid hemorrhage-induced oxidative brain damage in rats. J Neurotrauma; 2010 Jun;27(6):1143-55
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In plasma samples, neuron-specific enolase (NSE), S-100beta protein, TNF-alpha, and IL-1beta levels were evaluated, while forebrain tissue samples were taken for the measurement of malondialdehyde (MDA), glutathione (GSH), reactive oxygen species levels, myeloperoxidase (MPO), Na(+)-K(+)-ATPase activity, and DNA fragmentation ratio.
  • Brain tissue samples containing the basilar arteries were obtained for histological examination, while cerebrum and cerebellum were removed for the measurement of blood-brain barrier (BBB) permeability and brain water content.
  • Compared with the control group, the protein levels of NSE, S-100beta, TNF-alpha, and IL-1beta in plasma were also increased, while ghrelin treatment prevented all SAH-induced alterations observed both biochemically and histopathologically.
  • [MeSH-major] Brain / drug effects. Ghrelin / pharmacology. Inflammation / drug therapy. Subarachnoid Hemorrhage / drug therapy
  • [MeSH-minor] Animals. DNA Fragmentation. Enzyme-Linked Immunosorbent Assay. Interleukin-1beta / blood. Memory / drug effects. Memory / physiology. Naphthalenes. Nerve Growth Factors / blood. Neuroprotective Agents / pharmacology. Oxepins. Phosphopyruvate Hydratase / blood. Random Allocation. Rats. Rats, Wistar. Reactive Oxygen Species / metabolism. S100 Calcium Binding Protein beta Subunit. S100 Proteins / blood. Tumor Necrosis Factor-alpha / blood

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20205513.001).
  • [ISSN] 1557-9042
  • [Journal-full-title] Journal of neurotrauma
  • [ISO-abbreviation] J. Neurotrauma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 1-phenyl-1,4-epoxy-1H,4H-naphtho(1,8-de)(1,2)dioxepin; 0 / Ghrelin; 0 / Interleukin-1beta; 0 / Naphthalenes; 0 / Nerve Growth Factors; 0 / Neuroprotective Agents; 0 / Oxepins; 0 / Reactive Oxygen Species; 0 / S100 Calcium Binding Protein beta Subunit; 0 / S100 Proteins; 0 / Tumor Necrosis Factor-alpha; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


28. Ahn JS, Yang DH, Kim YK, Cho SH, Kim IY, Lee JJ, Chung IJ, Kim HJ: Multiple intracranial tuberculomas mimicking granulocytic sarcomas in acute myeloid leukemia. J Korean Med Sci; 2007 Sep;22 Suppl:S171-3
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • He complained of right-side paresthesia after the third consolidation chemotherapy without leukemic relapse and fever.
  • MR imaging of the brain showed multiple ring-enhanced lesions in the cerebrum, cerebellar hemisphere, and pons.
  • The lesions appeared to mimic a metastatic tumor or abscess.
  • He was treated with anti-tuberculosis medication and a high dose of steroid.
  • Paresthesia improved, and follow-up brain MR imaging showed the decreased size and numbers of ring-enhanced lesions and improvement of perilesional edema 1 month after treatment.
  • [MeSH-major] Brain Neoplasms / diagnosis. Leukemia, Myeloid, Acute / complications. Sarcoma, Myeloid / diagnosis. Tuberculoma, Intracranial / diagnosis
  • [MeSH-minor] Antitubercular Agents / therapeutic use. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Middle Aged

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Oncol. 2000 May;17(2):111-6 [10871816.001]
  • [Cites] Bone Marrow Transplant. 2001 Jun;27(12):1293-7 [11548848.001]
  • [Cites] Arq Neuropsiquiatr. 2002 Sep;60(3-B):852-5 [12364961.001]
  • [Cites] J Pediatr Hematol Oncol. 2004 Jan;26(1):64-7 [14707718.001]
  • [Cites] South Med J. 1988 Oct;81(10):1239-44 [3051426.001]
  • [Cites] No To Shinkei. 2006 Sep;58(9):797-801 [17052008.001]
  • [Cites] Radiol Clin North Am. 1995 Jul;33(4):733-52 [7610242.001]
  • [Cites] Leuk Lymphoma. 1999 Mar;33(1-2):187-92 [10194137.001]
  • [Cites] Surg Neurol. 2005;64 Suppl 2:S109-12 [16256830.001]
  • [Cites] No To Shinkei. 2006 Mar;58(3):225-30 [16629447.001]
  • [Cites] Clin Neurol Neurosurg. 2006 Jun;108(4):353-7 [16644403.001]
  • [Cites] Surg Neurol. 1990 Dec;34(6):383-9 [2244302.001]
  • (PMID = 17923749.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antitubercular Agents
  • [Other-IDs] NLM/ PMC2694373
  •  go-up   go-down


29. Michelucci R: Optimizing therapy of seizures in neurosurgery. Neurology; 2006 Dec 26;67(12 Suppl 4):S14-8
MedlinePlus Health Information. consumer health - Epilepsy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optimizing therapy of seizures in neurosurgery.
  • The use of antiepileptic drugs (AEDs) in the neurosurgical setting has a number of implications, including their possible role in the prevention of seizures after acute cerebral insults or brain tumors and the potential for toxicity and interactions when these agents are administered in association with radiotherapy or chemotherapy.
  • 1) AEDs should be prescribed on a short-term basis to prevent seizures occurring within the first week after a cerebral insult (trauma, neurosurgical procedure) but are ineffective to avoid true post-traumatic epilepsy or first seizures in patients with primary or secondary cerebral neoplasms.
  • The newly developed AEDs that are devoid of hepatic metabolism, such as levetiracetam and gabapentin, are now recommended because of good results in preliminary studies and because they do not show interactions with anticancer agents.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Epilepsy / drug therapy. Epilepsy / etiology. Neurosurgical Procedures / adverse effects
  • [MeSH-minor] Anticonvulsants / adverse effects. Anticonvulsants / therapeutic use. Brain Neoplasms / complications. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Cerebellum / surgery. Craniocerebral Trauma / complications. Drug Interactions. Humans. Radiation Injuries

  • Genetic Alliance. consumer health - Seizures.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17190915.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Antineoplastic Agents
  • [Number-of-references] 40
  •  go-up   go-down


30. Hentschel S, Toyota B: Intracranial malignant glioma presenting as subarachnoid hemorrhage. Can J Neurol Sci; 2003 Feb;30(1):63-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Cerebral aneurysms are the predominant cause of spontaneous subarachnoid hemorrhage (SAH).
  • Cerebral neoplasms are clearly on this list but are most commonly meningiomas or metastatic lesions.
  • This article details a case of a neoplasm that presented exclusively with SAH.
  • CLINICAL PRESENTATION: A 40-year-old male presented with a SAH with normal cerebral angiography.
  • CONCLUSION: An affirmation is made that patients experiencing 'angiographically-negative' SAH should undergo MRI, occasionally on a serial basis, to exclude other etiologies for hemorrhage, including neoplasia.
  • [MeSH-major] Brain Neoplasms / diagnosis. Oligodendroglioma / diagnosis. Subarachnoid Hemorrhage / etiology
  • [MeSH-minor] Adult. Anticonvulsants / therapeutic use. Cerebral Angiography. Humans. Magnetic Resonance Imaging. Male. Neurosurgical Procedures. Seizures / drug therapy. Seizures / etiology

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12619787.001).
  • [ISSN] 0317-1671
  • [Journal-full-title] The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
  • [ISO-abbreviation] Can J Neurol Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Anticonvulsants
  •  go-up   go-down


31. Hayakawa H, Obama K, Tara M: [Intradural recurrence of multiple myeloma during the hematological complete remission]. Rinsho Ketsueki; 2002 Nov;43(11):1009-13
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pretreatment examination revealed IgG-lambda type M-protein, Bence-Jones protein and the posterior mediastinum tumor.
  • As a result of VAD, MP, interferon and radiation therapy, he had a hematological complete remission.
  • After 21 months, he developed intradural relapse at cauda equina and cerebrum.
  • Many plasma cells and IgG-lambda type M-protein were detected in the cerebrospinal fluid.
  • Laboratory examinations showed a complete remission except for cerebral and meningeal involvement.
  • The myeloma cells might have infiltrated the intradural space at diagnosis and expanded in the central nervous system despite chemotherapy.
  • Because reported cases with cerebral and meningeal myeloma are increasing according to the recent advance of treatment, we must pay attention to the meningeal myeloma.
  • [MeSH-major] Brain Neoplasms / etiology. Cauda Equina. Multiple Myeloma / etiology. Peripheral Nervous System Neoplasms / etiology

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12508488.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 14
  •  go-up   go-down


32. Hukin J, Siffert J, Velasquez L, Zagzag D, Allen J: Leptomeningeal dissemination in children with progressive low-grade neuroepithelial tumors. Neuro Oncol; 2002 10;4(4):253-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our purpose is to describe the incidence and clinical features of leptomeningeal dissemination (LM) in children with progressive low-grade neuroepithelial tumor (LGN).
  • Satisfactorily followed data were obtained on 427 of the 588 patients with localized LGN at diagnosis between 1986 and 1998, 177 (42%) of whom developed progressive or recurrent disease.
  • The primary tumor sites were diencephalon (6), brainstem (3), cerebellum (2), cerebrum (1), and spinal cord (1).
  • Management included chemotherapy (2) or radiotherapy (3) or both (7); 1 patient received only radical resections of symptomatic lesions.
  • We strongly urge that for optimum treatment planning all patients with recurrent LGN be staged with an enhanced spine and brain MRI before adjuvant therapy is initiated.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Meningeal Neoplasms / secondary. Neoplasms, Neuroepithelial / secondary
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Combined Modality Therapy. Disease Progression. Female. Humans. Infant. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / therapy. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12356355.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1920666
  •  go-up   go-down


33. Ito A, Saito S, Masuko T, Oh-Eda M, Matsuura T, Satoh M, Nejad FM, Enomoto T, Orikasa S, Hakomori SI: Monoclonal antibody (5F3) defining renal cell carcinoma-associated antigen disialosyl globopentaosylceramide (V3NeuAcIV6NeuAcGb5), and distribution pattern of the antigen in tumor and normal tissues. Glycoconj J; 2001 Jun;18(6):475-85
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monoclonal antibody (5F3) defining renal cell carcinoma-associated antigen disialosyl globopentaosylceramide (V3NeuAcIV6NeuAcGb5), and distribution pattern of the antigen in tumor and normal tissues.
  • Renal cell carcinoma (RCC) has been characterized by high expression of three types of disialogangliosides: two based on lacto-series type 1 structure (disialosyl Lc(4), GalNAc disialosyl Lc(4)), the other based on globo-series structure (disialosyl globopentaosylceramide; disialosyl Gb5).
  • 5F3 strongly stained 19 of 41 cases of primary RCC tissue.
  • It reacted with proximal tubules (but not distal tubules) of kidney, microglial cells of cerebrum and cerebellum, goblet cells of stomach and intestine, smooth muscle of various organs.
  • Immunostaining of RCC tissue by mAb 5F3, in combination with staining by other antibodies directed to globo-series and lacto-series structures, has prognostic significance in defining metastatic potential of RCC.
  • [MeSH-major] Antibodies, Monoclonal / immunology. Antigens, Neoplasm / immunology. Carcinoma, Renal Cell / chemistry. Carcinoma, Renal Cell / immunology. Gangliosides / analysis. Gangliosides / immunology
  • [MeSH-minor] Antibody Specificity. Cell Line. Enzyme-Linked Immunosorbent Assay. Flow Cytometry. Glycosphingolipids / immunology. Humans. Immunohistochemistry. Magnetic Resonance Spectroscopy. Neoplasm Metastasis. Organ Specificity. Prognosis. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1996 Dec 1;56(23):5309-18 [8968075.001]
  • [Cites] J Exp Med. 1999 Sep 20;190(6):793-802 [10499918.001]
  • [Cites] Tohoku J Exp Med. 1999 Oct;189(2):95-105 [10775053.001]
  • [Cites] Nihon Hinyokika Gakkai Zasshi. 1993 Jul;84(7):1211-8 [8394948.001]
  • [Cites] J Biol Chem. 1994 Feb 25;269(8):5644-52 [7509790.001]
  • [Cites] Biochemistry. 1986 May 20;25(10):2859-66 [3087411.001]
  • [Cites] Urol Res. 1989;17(5):317-24 [2815432.001]
  • [Cites] Anal Biochem. 1980 Dec;109(2):399-402 [7224165.001]
  • [Cites] Int J Cancer. 1991 Sep 30;49(3):329-34 [1917130.001]
  • [Cites] Jpn J Cancer Res. 1997 Jul;88(7):652-9 [9310138.001]
  • [Cites] Arch Biochem Biophys. 1994 Jul;312(1):125-34 [8031119.001]
  • [Cites] Cancer Res. 1988 Nov 1;48(21):6154-60 [3167861.001]
  • [Cites] Nihon Hinyokika Gakkai Zasshi. 1991 Apr;82(4):613-9 [2051699.001]
  • [Cites] J Biol Chem. 2001 May 18;276(20):16695-703 [11278988.001]
  • [Cites] J Biol Chem. 1957 May;226(1):497-509 [13428781.001]
  • [Cites] FEBS Lett. 2001 Jun 1;498(1):116-20 [11389909.001]
  • (PMID = 12084983.001).
  • [ISSN] 0282-0080
  • [Journal-full-title] Glycoconjugate journal
  • [ISO-abbreviation] Glycoconj. J.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA80054
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / Gangliosides; 0 / Glycosphingolipids; 0 / sialogangliosides
  •  go-up   go-down


34. Shuangshoti S, Rushing EJ, Mena H, Olsen C, Sandberg GD: Supratentorial extraventricular ependymal neoplasms: a clinicopathologic study of 32 patients. Cancer; 2005 Jun 15;103(12):2598-605
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Supratentorial extraventricular ependymal neoplasms: a clinicopathologic study of 32 patients.
  • BACKGROUND: Published research on the clinicopathologic features of extraventricular ependymal neoplasms of the cerebral hemispheres has been scant.
  • The left cerebral hemisphere was 1.5 times more commonly involved.
  • Ki-67 proliferation index paralleled tumor grade.
  • Flow cytometry performed in 27 tumors revealed diploidy in 20 cases and aneuploidy in 4 cases (3 anaplastic and 1 classic ependymomas), with S-phase fraction ranging from 0.2-9.7.
  • Eleven subjects were additionally treated with radiotherapy, and 3 with chemotherapy.
  • CONCLUSIONS: The results of the current study suggest that there is no significant relation between histopathology, Ki-67 proliferation index, p53 immunolabeling, tumor ploidy, and biologic behavior.
  • [MeSH-major] Brain Neoplasms / pathology. Cerebral Ventricle Neoplasms / pathology. Ependymoma / pathology. Glioma, Subependymal / pathology. Supratentorial Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Proliferation. Child. Child, Preschool. Female. Flow Cytometry. Humans. Infant. Ki-67 Antigen / metabolism. Male. Middle Aged. Ploidies. Prognosis. S Phase. Tumor Suppressor Protein p53

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published 2005 by the American Cancer Society.
  • (PMID = 15861411.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


35. Hidaka T, Nakamura T, Shima T, Sumiya S, Saito S: Cerebral metastasis from a primary adenocarcinoma of the fallopian tube. Gynecol Oncol; 2004 Oct;95(1):260-3
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebral metastasis from a primary adenocarcinoma of the fallopian tube.
  • BACKGROUND: Primary adenocarcinoma of the fallopian tube is a rare disease, and cerebral metastasis from this tumor is an extremely rare event.
  • CASE: A 61-year-old female, who had been thought to be in a disease-free state after the initial treatment for stage IIIc fallopian tube adenocarcinoma, presented with severe headache, dizziness, nausea, and vomiting.
  • Brain CT and MRI revealed solitary metastatic lesion in the cerebrum, which was the only site of recurrence.
  • It was removed surgically, followed by platinum-based combination chemotherapy, and a clinical remission was achieved for 36 months.
  • CONCLUSION: Attention should be paid to the possibility of cerebral metastasis in patients who develop neurogenic signs and symptoms.
  • Prolonged survival could be achieved with aggressive treatment containing surgical debulking and adjuvant chemotherapy for solitary cerebral metastasis.
  • [MeSH-major] Adenocarcinoma / secondary. Brain Neoplasms / secondary. Fallopian Tube Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15385143.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Miyake Y, Okoshi Y, Machino T, Chiba S: Treatment of central nervous system lymphoma in rats with intraventricular rituximab and serum. Int J Hematol; 2010 Oct;92(3):474-80
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of central nervous system lymphoma in rats with intraventricular rituximab and serum.
  • Raji, a CD20-positive lymphoma cell line, was inoculated into the cerebrum of F344 (rnu/rnu) nude rats.
  • Intraventricularly administered RTX was localized specifically at the lymphoma lesions, indicating that RTX penetrated the ependymal layer of the lateral ventricle to reach the tumor lesion, where it specifically bound to the lymphoma cells.
  • Intraventricular administration of RTX and serum in a rat/human CNS lymphoma model might be a potential novel treatment for CNS lymphomas of B cell origin.
  • [MeSH-major] Antibodies, Monoclonal, Murine-Derived / administration & dosage. Antibodies, Monoclonal, Murine-Derived / therapeutic use. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Central Nervous System Neoplasms / drug therapy. Lymphoma, B-Cell / drug therapy. Serum / metabolism
  • [MeSH-minor] Animals. Cell Line, Tumor. Humans. Rats. Rats, Nude. Rituximab

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Immunol Immunother. 2002 Mar;51(1):15-24 [11845256.001]
  • [Cites] Expert Rev Neurother. 2009 Oct;9(10):1497-509 [19831839.001]
  • [Cites] Blood. 2000 Jun 15;95(12):3900-8 [10845926.001]
  • [Cites] Leukemia. 1998 Dec;12(12):2029-33 [9844934.001]
  • [Cites] Blood. 1994 Jan 15;83(2):435-45 [7506951.001]
  • [Cites] Glia. 1998 Jan;22(1):72-85 [9436789.001]
  • [Cites] J Neurooncol. 1999 Jun;43(2):153-60 [10533727.001]
  • [Cites] Cell Immunol. 2000 Aug 25;204(1):55-63 [11006018.001]
  • [Cites] EMBO J. 1988 Mar;7(3):711-7 [2456210.001]
  • [Cites] Blood. 2002 Feb 1;99(3):1038-43 [11807010.001]
  • [Cites] Blood. 2003 Feb 1;101(3):949-54 [12393572.001]
  • [Cites] Haematologica. 2004 Jun;89(6):753-4 [15194546.001]
  • [Cites] Pharm Res. 2005 Jul;22(7):1011-37 [16028003.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2008 Nov;49(11):4738-45 [18552383.001]
  • [Cites] J Immunol. 2001 Feb 15;166(4):2717-26 [11160337.001]
  • [Cites] Cancer Sci. 2006 Jan;97(1):80-3 [16367925.001]
  • [Cites] J Neurooncol. 2006 Jan;76(2):131-8 [16284923.001]
  • [Cites] J Exp Med. 1988 Jun 1;167(6):1975-80 [3260267.001]
  • [Cites] Cancer Sci. 2007 Sep;98(9):1368-72 [17640305.001]
  • [Cites] J Clin Oncol. 2007 Apr 10;25(11):1350-6 [17312328.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1793-800 [15172969.001]
  • [Cites] Adv Drug Deliv Rev. 1999 Apr 5;36(2-3):211-227 [10837717.001]
  • [Cites] Int J Hematol. 2009 Jun;89(5):577-83 [19353238.001]
  • [Cites] J Immunol. 2003 Aug 1;171(3):1581-7 [12874252.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1314-9 [11830481.001]
  • [Cites] Leuk Lymphoma. 2001 Aug;42(4):731-8 [11697503.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):4027-35 [16818702.001]
  • [Cites] J Cereb Blood Flow Metab. 1997 Jul;17(7):713-31 [9270488.001]
  • [Cites] Mol Genet Metab. 2005 Sep-Oct;86(1-2):141-9 [16006167.001]
  • [Cites] Blood. 2003 Jan 15;101(2):466-8 [12393404.001]
  • [Cites] Clin Cancer Res. 2009 Mar 15;15(6):1989-97 [19276270.001]
  • [Cites] Glia. 1998 Apr;22(4):348-59 [9517567.001]
  • [Cites] Clin Cancer Res. 2003 Dec 15;9(17):6567-71 [14695162.001]
  • [Cites] Jpn J Clin Oncol. 2008 May;38(5):373-80 [18413337.001]
  • (PMID = 20820968.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


37. Hukin J, Siffert J, Cohen H, Velasquez L, Zagzag D, Allen J: Leptomeningeal dissemination at diagnosis of pediatric low-grade neuroepithelial tumors. Neuro Oncol; 2003 07;5(3):188-96
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The charts were reviewed and patients contacted to validate the demographic data, treatment, and clinical status.
  • The distribution of LM patients by primary tumor site was diencephalon, 5; cerebrum, 2; spinal cord, 3; brainstem, 2; and cerebellum, 1.
  • Six of 8 patients with LM had durable objective responses to chemotherapy.
  • We suggest that staging be considered in the following circumstances: diencephalic primary site, unexplained hydrocephalus, clinical features suggestive of LM, and before adjuvant therapy is initiated.
  • The prognosis for children with LM at diagnosis is favorable, and its identification alters therapeutic strategies.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Meningeal Neoplasms / diagnosis. Neoplasms, Neuroepithelial / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12816725.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1920691
  •  go-up   go-down


38. Oliveira AM, Scheithauer BW, Salomao DR, Parisi JE, Burger PC, Nascimento AG: Primary sarcomas of the brain and spinal cord: a study of 18 cases. Am J Surg Pathol; 2002 Aug;26(8):1056-63
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Median tumor size was 4 cm (range 1.3-8 cm).
  • Fifteen tumors arose in the cerebrum (83%), two in the cerebellum, and one in the spinal cord.
  • Histopathologically, the most common tumor types included fibrosarcoma (six), malignant fibrous histiocytoma (five), and undifferentiated sarcoma (three).
  • All patients had subtotal to gross total tumor resection; 16 also received radiotherapy and/or chemotherapy.
  • Survival at 5 years for patients with high-grade tumors was 28% compared with 83% for those with low-grade neoplasms (p = 0.03).
  • Most involve the cerebrum and show fibrous, "fibrohistiocytic," or no specific differentiation.
  • [MeSH-major] Brain Neoplasms / pathology. Sarcoma / pathology. Spinal Cord Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Cerebellar Neoplasms / pathology. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis


39. Sabarinathan D, Mahalakshmi P, Vanisree AJ: Naringenin promote apoptosis in cerebrally implanted C6 glioma cells. Mol Cell Biochem; 2010 Dec;345(1-2):215-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Naringenin (NGEN), a naturally occurring citrus flavonone, has shown cytotoxicity in various human cancer cell lines as well as inhibitory effects on tumor growth.
  • It has been also shown to access the brain and there is an increasing interest in its therapeutic applications.
  • [MeSH-major] Apoptosis / drug effects. Cerebrum / pathology. Flavanones / pharmacology. Gene Expression Regulation, Neoplastic / drug effects. Glioma / drug therapy
  • [MeSH-minor] Animals. Apoptosis Regulatory Proteins / analysis. Apoptosis Regulatory Proteins / drug effects. Caspases / analysis. Caspases / drug effects. Cell Line, Tumor / transplantation. Estrogen Antagonists. Flavones. Microscopy, Electron, Transmission. Neoplasms, Experimental / drug therapy. Rats

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Prolif. 2009 Apr;42(2):229-40 [19317806.001]
  • [Cites] Biochem Pharmacol. 2002 Sep;64(5-6):765-70 [12213568.001]
  • [Cites] Cancer. 1994 Oct 1;74(7):1921-6 [7521787.001]
  • [Cites] Ann Hematol. 2005 Oct;84(10):627-39 [16041532.001]
  • [Cites] Carcinogenesis. 1996 Jun;17(6):1199-213 [8681433.001]
  • [Cites] Apoptosis. 2005 Oct;10 (5):1019-29 [16151637.001]
  • [Cites] Methods Mol Biol. 1995;49:423-37 [8563826.001]
  • [Cites] Biol Pharm Bull. 2005 Mar;28(3):527-30 [15744083.001]
  • [Cites] Acta Neuropathol. 1993;86(2):117-25 [8213067.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Jul;63(1):72-80 [17478095.001]
  • [Cites] Toxicol Lett. 2006 Oct 10;166(2):131-9 [16860949.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1309-12 [9721092.001]
  • [Cites] Curr Biol. 2001 Oct 2;11(19):R795-805 [11591341.001]
  • [Cites] Toxicol Appl Pharmacol. 2008 Mar 1;227(2):219-28 [18031783.001]
  • [Cites] Front Biosci. 2007 Jan 01;12:1935-45 [17127432.001]
  • [Cites] Int J Cancer. 2001 Apr 1;92(1):130-8 [11279616.001]
  • [Cites] Mol Cell Biochem. 2009 Jan;320(1-2):197-203 [18759062.001]
  • [Cites] Biochem Biophys Res Commun. 2003 May 9;304(3):455-61 [12729579.001]
  • [Cites] J Neurooncol. 2001 Jul;53(3):275-87 [11718260.001]
  • [Cites] Eur J Cancer Prev. 1998 Feb;7(1):3-8 [9511846.001]
  • [Cites] Neurosurgery. 1985 Sep;17(3):413-8 [4047352.001]
  • [Cites] N Engl J Med. 2005 Aug 25;353(8):811-22 [16120861.001]
  • [Cites] J Clin Invest. 2005 Oct;115(10):2648-55 [16200198.001]
  • [Cites] J Agric Food Chem. 1999 Jan;47(1):128-35 [10563860.001]
  • [Cites] J Neurochem. 2005 Jan;92(1):1-9 [15606891.001]
  • [Cites] Free Radic Biol Med. 2004 Mar 1;36(5):592-604 [14980703.001]
  • [Cites] Pathology. 2007 Dec;39(6):558-64 [18027258.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 Nov;131(11):765-71 [16049707.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5089-96 [9823317.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):19-30 [12086884.001]
  • [Cites] Pharm Res. 2008 Apr;25(4):740-51 [17674158.001]
  • [Cites] J Biol Chem. 1997 Mar 7;272(10):6578-83 [9045686.001]
  • (PMID = 20717707.001).
  • [ISSN] 1573-4919
  • [Journal-full-title] Molecular and cellular biochemistry
  • [ISO-abbreviation] Mol. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Estrogen Antagonists; 0 / Flavanones; 0 / Flavones; EC 3.4.22.- / Caspases; HN5425SBF2 / naringenin; S2V45N7G3B / flavone
  •  go-up   go-down


40. Essig M, Weber MA, von Tengg-Kobligk H, Knopp MV, Yuh WT, Giesel FL: Contrast-enhanced magnetic resonance imaging of central nervous system tumors: agents, mechanisms, and applications. Top Magn Reson Imaging; 2006 Apr;17(2):89-106
Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Brain tumors are one of the most common neoplasms in young adults and are associated with a high mortality and disability rate.
  • Magnetic resonance imaging (MRI) is widely accepted to be the most sensitive imaging modality in the assessment of cerebral neoplasms.
  • Because the detection, characterization, and exact delineation of brain tumors require a high lesion contrast that depends on the signal of the lesion in relation to the surrounding tissue, contrast media is given routinely.
  • Anatomical and functional, contrast agent-based MRI techniques allow for a better differential diagnosis, grading, and especially therapy decision, planing, and follow-up.
  • The underlying pathology of a disrupted blood-brain barrier and drug influences will be discussed.
  • An overview of the currently available contrast media and the influences of dosage, field strength, and application on the tumor tissue contrast will be given.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Contrast Media. Magnetic Resonance Imaging / methods

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17198225.001).
  • [ISSN] 0899-3459
  • [Journal-full-title] Topics in magnetic resonance imaging : TMRI
  • [ISO-abbreviation] Top Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Organometallic Compounds; AU0V1LM3JT / Gadolinium
  • [Number-of-references] 159
  •  go-up   go-down


41. Kobayashi H, Ishii N, Murata J, Saito H, Kubota KC, Nagashima K, Iwasaki Y: Cystic meningioangiomatosis. Pediatr Neurosurg; 2006;42(5):320-4
MedlinePlus Health Information. consumer health - Brain Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A case of cerebral meningioangiomatosis with rare cyst formation is reported.
  • A 14-year-old boy without any stigmata of neurofibromatosis type 2 presented intractable complex partial and generalized seizures since the age of 12 years.
  • Neuroradiological studies showed an abnormal cystic mass with calcification in the left frontal lobe of the cerebrum.
  • The tumor was located in the leptomeninges and cerebral cortex.
  • The patient underwent surgical treatment because medical treatment with phenytoin and sodium valproate was not sufficient to control the seizures.
  • [MeSH-major] Angiomatosis / surgery. Brain Diseases / surgery. Cerebral Cortex / surgery. Meninges / surgery
  • [MeSH-minor] Adolescent. Electroencephalography. Humans. Male. Seizures / drug therapy. Seizures / etiology. Seizures / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel.
  • (PMID = 16902347.001).
  • [ISSN] 1016-2291
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


42. Mineo JF, Scheffer A, Karkoutly C, Nouvel L, Kerdraon O, Trauet J, Bordron A, Dessaint JP, Labalette M, Berthou C, Labalette P: Using human CD20-transfected murine lymphomatous B cells to evaluate the efficacy of intravitreal and intracerebral rituximab injections in mice. Invest Ophthalmol Vis Sci; 2008 Nov;49(11):4738-45
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The treatment of primary central nervous system lymphoma (PCNSL) and its subset, primary intraocular lymphoma (PIOL), remains of limited efficiency, and salvage therapies are often used without prior testing in adequate animal models.
  • RESULTS: Inoculation of 38C13 CD20(+) cells in the eye or the brain resulted in tumor occurrence after a median of 15 days or 22 days, respectively, with histologic characteristics closely resembling those of PIOL and PCNSL.
  • Local rituximab injections eradicated tumor colonization in more than half the graft recipients and inhibited tumor progression significantly in the others compared with progression in mice that underwent grafting with the control 38C13 cell line (no human CD20 expression) and in mice that underwent grafting with 38C13 CD20(+) cells that received local injections of an irrelevant antibody (trastuzumab).
  • CONCLUSIONS: Inoculation of native or human CD20-transfected murine 38C13 cells in the vitreous or the brain of immunocompetent mice provides useful novel models for evaluating the biology and treatment of PIOL and PCNSL.
  • Intravitreal and intracerebral rituximab injections reduced tumor occurrence and growth in each model.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antigens, CD20 / immunology. Antineoplastic Agents / administration & dosage. Brain Neoplasms / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Animals. Antibodies, Monoclonal, Murine-Derived. Cell Line, Tumor. Cerebrum. Flow Cytometry. Immunohistochemistry. Injections. Mice. Mice, Inbred C3H. Neoplasms, Experimental. Rituximab. Treatment Outcome. Vitreous Body

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18552383.001).
  • [ISSN] 1552-5783
  • [Journal-full-title] Investigative ophthalmology & visual science
  • [ISO-abbreviation] Invest. Ophthalmol. Vis. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


43. Wong ST, Yuen SC, Fong D: Pathophysiological mechanism of ipsilateral cerebral and brainstem hemiatrophy in basal ganglia germ cell tumors: case report. Childs Nerv Syst; 2009 Jun;25(6):693-9
Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathophysiological mechanism of ipsilateral cerebral and brainstem hemiatrophy in basal ganglia germ cell tumors: case report.
  • It has been reported that basal ganglia germinomas and mixed germ cell tumors are associated with ipsilateral cerebral and brainstem hemiatrophy on presentation.
  • Several pathophysiological mechanisms including autoimmune process and direct tumor infiltration of the thalamus or the internal capsule have been postulated to explain this association.
  • Both of them presented with gradual onset of hemiparesis and had features of ipsilateral cerebral and brainstem hemiatrophy on imaging studies.
  • They underwent chemotherapy followed by reduced dose radiotherapy with good response.
  • DISCUSSION: Pathophysiological mechanisms of the associated ipsilateral cerebral and brainstem hemiatrophy are discussed.
  • The authors postulate that the gradual obliteration of the perforating arteries to the diencephalon especially the lenticulostriate arteries of the prebifurcation middle cerebral artery may be the major mechanism of the associated hemiatrophy.
  • [MeSH-major] Brain / pathology. Brain Neoplasms / pathology. Brain Stem / pathology. Cerebrum / pathology. Neoplasms, Germ Cell and Embryonal / pathology
  • [MeSH-minor] Atrophy. Cerebral Angiography. Child. Fluorodeoxyglucose F18. Functional Laterality. Gadolinium. Humans. Magnetic Resonance Imaging. Male. Positron-Emission Tomography

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuroradiology. 1998 Aug;40(8):507-11 [9763338.001]
  • [Cites] J Neurooncol. 1990 Apr;8(2):153-61 [2358850.001]
  • [Cites] Pediatr Radiol. 2006 Apr;36(4):325-30 [16463029.001]
  • [Cites] J Comput Assist Tomogr. 1988 Sep-Oct;12 (5):740-3 [3170832.001]
  • [Cites] Clin Anat. 2001 May;14(3):190-5 [11301466.001]
  • [Cites] J Mal Vasc. 1994;19(4):315-9 [7852877.001]
  • [Cites] AJNR Am J Neuroradiol. 1983 May-Jun;4(3):478-80 [6410776.001]
  • [Cites] Oncologist. 2008 Jun;13(6):690-9 [18586924.001]
  • [Cites] Pediatr Neurosurg. 2004 Nov-Dec;40(6):306-11 [15821363.001]
  • [Cites] Radiology. 1989 Jul;172(1):179-82 [2740501.001]
  • [Cites] Neuropediatrics. 2007 Apr;38(2):100-4 [17712739.001]
  • [Cites] Childs Nerv Syst. 2008 Mar;24(3):303-6 [17882439.001]
  • [Cites] J Neurosurg. 2000 Apr;92(4):676-87 [10761659.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):803-8 [15936563.001]
  • [Cites] J Neurosurg. 1998 Jan;88(1):126-8 [9420084.001]
  • [Cites] Childs Nerv Syst. 2007 Jan;23(1):105-8 [17058090.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 Oct;24(9):1909-11 [14561627.001]
  • [Cites] Stroke. 1985 Nov-Dec;16(6):1022-9 [4089920.001]
  • [Cites] Eur J Neurol. 2006 Aug;13(8):904-7 [16879304.001]
  • [Cites] Surg Radiol Anat. 1998;20(6):393-8 [9932322.001]
  • [Cites] J Neurosurg. 1978 Mar;48(3):443-9 [632867.001]
  • [Cites] Eur Radiol. 2006 Mar;16(3):592-7 [16220209.001]
  • [Cites] Childs Nerv Syst. 2007 Nov;23(11):1341-5 [17609967.001]
  • [Cites] Neurology. 1998 Jun;50(6):1699-708 [9633714.001]
  • [Cites] Surg Neurol. 1986 May;25(5):495-500 [2421426.001]
  • [Cites] No Shinkei Geka. 1977 Oct;5(11):1181-7 [917218.001]
  • [Cites] Acta Neurochir (Wien). 2002 Feb;144(2):145-50; discussion 150 [11862514.001]
  • [Cites] Surg Neurol. 1987 Mar;27(3):291-4 [3810463.001]
  • [Cites] Radiology. 1988 Jul;168(1):199-202 [3380957.001]
  • [Cites] Pediatr Neurol. 1999 Apr;20(4):312-4 [10328283.001]
  • [Cites] Neuroradiology. 2002 May;44(5):389-94 [12012122.001]
  • [Cites] Cancer. 2005 Nov 15;104(10):2156-67 [16220552.001]
  • [Cites] Childs Nerv Syst. 2008 Jan;24(1):71-8 [17906866.001]
  • [Cites] Childs Nerv Syst. 1990 Jan;6(1):3-7 [2178773.001]
  • [Cites] AJNR Am J Neuroradiol. 1994 Sep;15(8):1435-41 [7985560.001]
  • [Cites] J Neurooncol. 2007 May;83(1):71-9 [17245622.001]
  • [Cites] J Clin Neurosci. 1999 Mar;6(2):162-4 [18639143.001]
  • (PMID = 19139902.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18; AU0V1LM3JT / Gadolinium
  •  go-up   go-down


44. Chung WJ, Sontheimer H: Sulfasalazine inhibits the growth of primary brain tumors independent of nuclear factor-kappaB. J Neurochem; 2009 Jul;110(1):182-93
Hazardous Substances Data Bank. SULFASALAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This does not change when gliomas are implanted into the cerebrum of severe combined immun-deficient mice.
  • Both drugs inhibited cystine uptake causing a chronic depletion of intracellular GSH and consequently compromised cellular redox defense which stymied tumor growth.
  • This data suggests that system x(c)(-) is a promising therapeutic target in gliomas and possibly other cancers and that it can be pharmacologically inhibited by Sulfasalazine, an FDA-approved drug.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int Immunopharmacol. 2002 Oct;2(11):1509-20 [12433052.001]
  • [Cites] Nat Rev Immunol. 2002 Oct;2(10):725-34 [12360211.001]
  • [Cites] NMR Biomed. 2003 Feb;16(1):12-8 [12577293.001]
  • [Cites] J Neurooncol. 2003 Jan;61(2):151-60 [12622454.001]
  • [Cites] J Neurosci. 2003 Apr 15;23(8):3394-406 [12716947.001]
  • [Cites] Trends Neurosci. 2003 Oct;26(10):543-9 [14522147.001]
  • [Cites] Mol Cell. 2003 Oct;12(4):829-39 [14580335.001]
  • [Cites] Anticancer Res. 2003 Nov-Dec;23(6C):4571-9 [14981898.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89 [15977639.001]
  • [Cites] J Neurosci. 2005 Aug 3;25(31):7101-10 [16079392.001]
  • [Cites] Science. 2005 Sep 16;309(5742):1857-61 [16166517.001]
  • [Cites] Nature. 2006 May 25;441(7092):431-6 [16724054.001]
  • [Cites] Prostate. 2007 Feb 1;67(2):162-71 [17075799.001]
  • [Cites] Oncogene. 2007 Jan 25;26(4):571-82 [16909119.001]
  • [Cites] Cancer Res. 2007 Oct 1;67(19):9463-71 [17909056.001]
  • [Cites] Cell. 2008 Feb 8;132(3):344-62 [18267068.001]
  • [Cites] J Cell Physiol. 2008 Jun;215(3):593-602 [18181196.001]
  • [Cites] J Neurochem. 2008 Apr;105(2):287-95 [18284616.001]
  • [Cites] Br J Cancer. 2008 Aug 5;99(3):464-72 [18648370.001]
  • [Cites] Oncogene. 2009 Jan 29;28(4):599-609 [19015640.001]
  • [Cites] J Nutr. 2004 Mar;134(3):489-92 [14988435.001]
  • [Cites] Lab Invest. 2004 Aug;84(8):941-51 [15184909.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5595-603 [15328202.001]
  • [Cites] N Engl J Med. 1973 Dec 20;289(25):1374-5 [4201791.001]
  • [Cites] Drugs. 1986;32 Suppl 1:18-26 [2877850.001]
  • [Cites] Neuron. 1988 Oct;1(8):623-34 [2908446.001]
  • [Cites] Science. 1997 Oct 31;278(5339):860-6 [9346484.001]
  • [Cites] J Clin Invest. 1998 Mar 1;101(5):1163-74 [9486988.001]
  • [Cites] Cancer Res. 1998 Nov 1;58(21):4871-9 [9809993.001]
  • [Cites] Neurology. 1998 Nov;51(5):1342-52 [9818858.001]
  • [Cites] Clin Chem. 1999 Jan;45(1):7-17 [9895331.001]
  • [Cites] J Biol Chem. 1999 Apr 23;274(17):11455-8 [10206947.001]
  • [Cites] J Biol Chem. 1999 Sep 10;274(37):26448-53 [10473604.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4383-91 [10485487.001]
  • [Cites] Cell Biochem Funct. 2004 Nov-Dec;22(6):343-52 [15386533.001]
  • [Cites] Nat Rev Cancer. 2005 Apr;5(4):297-309 [15803156.001]
  • [Cites] J Neurosci. 1999 Dec 15;19(24):10767-77 [10594060.001]
  • [Cites] Br J Pharmacol. 1999 Dec;128(7):1361-9 [10602313.001]
  • [Cites] J Neurooncol. 2000 Mar;47(1):11-22 [10930095.001]
  • [Cites] Gastroenterology. 2000 Nov;119(5):1209-18 [11054378.001]
  • [Cites] Prog Neurobiol. 2001 Sep;65(1):1-105 [11369436.001]
  • [Cites] Biochim Biophys Acta. 2001 Jun 6;1512(2):335-44 [11406111.001]
  • [Cites] Pflugers Arch. 2001 May;442(2):286-96 [11417227.001]
  • [Cites] Nat Med. 2001 Sep;7(9):1010-5 [11533703.001]
  • [Cites] Nature. 2001 Sep 6;413(6851):78-83 [11544529.001]
  • [Cites] Leukemia. 2001 Oct;15(10):1633-40 [11587223.001]
  • [Cites] J Neurosurg. 2002 May;96(5):909-17 [12005399.001]
  • [Cites] Wien Klin Wochenschr. 2002 Nov 30;114(21-22):911-6 [12528323.001]
  • (PMID = 19457125.001).
  • [ISSN] 1471-4159
  • [Journal-full-title] Journal of neurochemistry
  • [ISO-abbreviation] J. Neurochem.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / P30 NS057098; United States / NICHD NIH HHS / HD / P30 HD038985; United States / NICHD NIH HHS / HD / P30 HD038985-09; United States / NINDS NIH HHS / NS / NS052634-06; United States / NINDS NIH HHS / NS / P30 NS057098-05; United States / NINDS NIH HHS / NS / R01 NS052634-06; United States / NINDS NIH HHS / NS / R01 NS052634; United States / NICHD NIH HHS / HD / HD038985-09; United States / NINDS NIH HHS / NS / R01-NS052634
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Amino Acid Transport System y+; 0 / Antineoplastic Agents; 0 / Cytokines; 0 / Gastrointestinal Agents; 0 / NF-kappa B; 0 / Slc7a11 protein, mouse; 3XC8GUZ6CB / Sulfasalazine; EC 2.7.11.10 / I-kappa B Kinase
  • [Other-IDs] NLM/ NIHMS263378; NLM/ PMC3031868
  •  go-up   go-down


45. Belzunegui J, López L, Paniagua I, Intxausti JJ, Maíz O: Efficacy of infliximab and adalimumab in the treatment of a patient with severe neuro-Behçet's disease. Clin Exp Rheumatol; 2008 Jul-Aug;26(4 Suppl 50):S133-4
Hazardous Substances Data Bank. Infliximab .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of infliximab and adalimumab in the treatment of a patient with severe neuro-Behçet's disease.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Behcet Syndrome / drug therapy. Brain Diseases / drug therapy. Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • [MeSH-minor] Adalimumab. Adult. Antibodies, Monoclonal, Humanized. Cerebrum. Humans. Infliximab. Male. Paresis / etiology

  • Genetic Alliance. consumer health - Behcet's Disease.
  • MedlinePlus Health Information. consumer health - Behcet's Syndrome.
  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19026138.001).
  • [ISSN] 0392-856X
  • [Journal-full-title] Clinical and experimental rheumatology
  • [ISO-abbreviation] Clin. Exp. Rheumatol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Tumor Necrosis Factor-alpha; B72HH48FLU / Infliximab; FYS6T7F842 / Adalimumab
  •  go-up   go-down






Advertisement